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ABSTRACT 
 Monocyte chemoattractant protein-1 is critical for monocyte recruitment to the lungs 
in response to bacterial infection.  MCP-1 is also essential for protective neutrophil 
recruitment to the lungs during Escherichia coli and Klebsiella pneumoniae infection.  
Staphylococcus aureus pneumonia, specifically strain USA300, carries a high morbidity and 
mortality rate and is an important pathogen in hospital/ventilator and community acquired 
pneumonia.  In the current study, we investigated the role of MCP-1 in pulmonary innate 
immunity to S. aureus in C57Bl/6, MCP-1-/- and MCP-1 AB blocked mice.  As compared to 
C57Bl/6, MCP-1-/- mice showed increased concentrations of neutrophils in the airways and 
lung parenchyma as assessed by nucleated cell concentrations in BALF, myeloperoxidase 
activity (MPO) in lung tissue, and lung histopathology, and increased concentrations of the 
pro-inflammatory cytokines TNF-α and IL-6.  However, this increase in inflammatory 
cytokines and augmented neutrophilic response did not correlate with increased bacterial 
clearance, as determined by CFUs from BALF, lung, liver and spleen.  MCP-1 AB blocked 
mice trended towards higher BALF nucleated cell counts and MPO activity in lung tissue, 
but were not significantly different from negative controls.  In conclusion, MCP-1 appears to 
be differentially regulated during bacterial pneumonia, and in an S. aureus model, MCP-1-/- 
mice have moderately enhanced neutrophilic inflammation which does not improve bacterial 
clearance.
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CHAPTER 1 
INTRODUCTION 
 
! Staphylococcus!aureus!is!a!leading!cause!of!bacterial!infection!worldwide,!and!in!the!United!States!is!the!principle!isolate!from!hospitalIassociated!bacterial!infections.1!!Among!the!spectrum!of!S.!aureus!disease!manifestations,!the!majority!are!skin!and!soft!tissue!infections,!however!other!sites!including!the!bloodstream!and!lower!respiratory!tract!are!also!wellIdescribed.1!Notably,!while!pneumonia!is!far!less!common!than!soft!tissue!infection,!it!is!responsible!for!the!majority!of!fatalities!associated!with!methicillin!resistant!strains!of!S.!aureus!(MRSA).!!In!2005!MRSA!strains!were!responsible!for!18,000!deaths!in!the!U.S.,!more!than!¾!of!which!were!due!to!pneumonia.2!! On!the!basis!of!pulse!field!gel!electrophoresis!(PFGE),!the!CDC!categorized!the!most!common!isolates!of!S.!aureus!using!the!USA!naming!system,!which!currently!includes!strains!USA100IUSA1200,!all!of!which!display!methicillin!resistance!with!the!exception!of!strains!USA900!and!USA1200.3!In!addition!to!PFGE!classification,!S.!aureus!strains!are!often!grouped!according!to!epidemiologic!associations,!namely!community!acquired!infections!!(CAIMRSA),!or!those!associated!with!hospitalization!or!ventilator!support!(HA/VAPIMRSA).!! Strain!USA300,!initially!described!in!the!1990s!as!a!sporadic!cause!of!community!acquired!infection!among!healthy!individuals,!continues!to!be!the!leading!cause!of!CAIMRSA!infections.2!Since!that!time,!however,!it!has!also!been!described!as!a!principle!strain!in!HA/VAPIMRSA!cases.!!In!a!2012!analysis!of!MRSA!isolates!from!251!intensive!care!unit!(ICU)!patients!USA300!was!the!second!most!common!isolate!(23.9%).4!HA/VAPIMRSA!pneumonia!has!a!high!mortality!rate!(up!to!37%!in!one!study)!compared!to!other!HA!bacterial!pneumonias,!and!is!also!a!large!drain!on!health!care!
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resources/costs,!with!HA/VAPIMRSA!cases!averaging!$8,000!more!in!medical!costs!than!pneumonia!caused!by!methicillin!sensitive!strains.4I6!! Gross!and!histopathologic!pulmonary!findings!in!USA300!pneumonia!are!distinctive!among!bacterial!pathogens,!consisting!of!severe!hemorrhage!and!necrosis!with!intralesional!bacteria!but!no!appreciable!suppurative/neutrophilic!response.7!!The!severity!of!USA300!pneumonia!is!not!reliant!solely!on!the!immunocompromised!nature!of!hospitalized!individuals,!as!it!causes!similar!lesions!in!otherwise!healthy!individuals!acquiring!infections!as!a!result!of!CAIMRSA.!!Methicillin!resistance!is!another!unlikely!explanation,!as!many!other!common!HA/VAP!MRSA!strains!actually!display!broader!antibiotic!resistance!to!multiple!drug!classes.4!!Ultimately!several!virulence!factors!likely!contribute!although!the!exact!pathologic!basis!for!the!necrotizing!hemorrhagic!features!of!USA300!remains!unclear.!!!
 Panton-Valentine leukocidin (PVL), is a virulence factor which has!received!much!research!attention, and is expressed by a large number of USA300 isolates, and by 
relatively few other MRSA or MSSA strains.8,9 PVL is a pore-forming toxin shown to cause 
apoptosis of neutrophils in low doses and neutrophil necrosis in high doses, which may 
provide an explanation for the paucity of neutrophils seen histologically in USA300 affected 
lungs.9,10 It is unlikely, however, to be the sole mediator, as similar pathologic lesions are 
described post-infection with USA300 strains not expressing PVL, and other virulence 
factors including phenol soluble modulins (PSMs) and the super antigen Selx have been 
shown experimentally to induce similar lesions.11,12!
! S.!aureus!pneumonia!has!an!acute!clinical!course!in!naturally!occurring!human!infections!and!animal!models.13!!As!such!innate!immune!defenses!generated!at!early!
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time!points!are!critical!for!bacterial!clearance!and!host!survival.!!!In!addition!to!soluble!mediators!such!as!complement,!collectins!and!ficolins,!S.!aureus!interacts!with!pulmonary!epithelial!cells!and!macrophages!via!pattern!recognition!receptors!(PRRs)!such!as!TLR2,!NOD2,!and!NLRP3,!initiating!proIinflammatory!signaling!cascades!which!upregulate!expression!of!genes!important!for!host!defense!and!leukocyte!recruitment. 
While undoubtedly some degree of pro-inflammatory signaling is necessary for bacterial 
clearance and neutrophil recruitment, it remains unclear which signaling cascades are vital, 
dispensable, or actually counter productive for protective immunity.  Interestingly while mice 
deficient in the TLR2 adaptor protein MYD88 are highly susceptible to systemic infection 
with S. aureus, these mice are able to control pulmonary infection with maintained 
cytokine/chemokine and neutrophil responses.14  In contrast NOD2-/- mice challenged intra-
tracheally with S. aureus do have diminished cytokine/chemokine responses and neutrophil 
influx, however, reduced inflammatory signaling in this model lead to improved bacterial 
clearance.15 !
 Despite its role in neutrophil chemotaxis and ability to augment neutrophil and 
macrophage mediated microbe killing, TNF-α levels were inversely correlated with outcome 
in one study, while in another publication mice deficient in TNFR1, the TNF-α receptor, 
cleared S. aureus more efficiently than wild type mice.13,16  Similarly there is an ill-defined 
tipping point at which a robust neutrophilic response transitions from protective to 
deleterious.  Left unchecked, neutrophils can impart as much harm to the surrounding tissue 
as to the pathogen via toxic mediators such as elastase, collagenase, and free radicals.1!
Ultimately the factors delineating what constitutes a protective versus harmful immune 
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response to S. aureus continue to be elusive, warranting further studies into the pulmonary 
innate immune response to this important pathogen.  
 Monocyte chemoattractant protein one (MCP-1) is a chemokine principally described 
as a monocyte chemattractant, but has also been shown to recruit neutrophils to the airways 
at early time points in E. coli and K. pneumoniae infection models, leading to generation of a 
robust and protective neutrophilic response.17,18 MCP-1 is constitutively produced in the 
lung, but production in epithelial cells and alveolar macrophages can also be upregulated 
downstream of pattern recognition receptor or inflammatory cytokine signaling mediated by 
substance including LPS and TNF-α.19 In a Pseudomonas aeruginosa pneumonia model, 
immunohistochemistry demonstrated strong labeling of intracytoplasmic MCP-1 in murine 
alveolar epithelial cells and alveolar macrophages post-infection.20  
 Secreted MCP-1 binds to its principal receptor CC chemokine receptor 2 (CCR2) 
present on a variety of cells including monocytes/macrophages, fibroblasts, epithelial and 
endothelial cells.19  CCR2 is a G-protein coupled receptor which is also integrated with 
JAK/STAT signaling cascades.21,22 While receptor signaling allows for mobilization of 
intracellular calcium stores necessary for polymerization of cytoskeletal components and 
chemotaxis, the cascades initiated on CCR2 binding can be multiple and diverse, with other 
important functions.21,22 For example, pulmonary epithelial cells stimulated with MCP-1 can 
upregulate mucus production, MCP-1 is up-regulated in atherosclerotic lesions, MCP-1 
levels correlate with progressive organ fibrosis in some models, and MCP-1 promotes 
angiongenesis and macrophage infiltration in gastric carcinoma.23-26  
 Anti-MCP-1 therapies including MCP-1 blocking antibodies and gene therapy have 
been developed to moderate chronic or deleterious inflammatory responses, fibrosis, 
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angiongenesis, and tumor burden. To date parenteral administration of anti-MCP-1 or MCP-1 
gene therapy have been utilized in a number of animal trials which collectively have 
produced many promising results including decreasing intimal proliferation in 
artheriosclerotic plaques, reducing vessel restenosis post-angioplasty, decreasing organ 
fibrosis, and reducing overall tumor burden and angiongenesis in cancer models.24-27 As these 
therapies progress towards human clinical trials, understanding the role of MCP-1 in innate 
immune defenses and delineating important risk factors for patients receiving such treatments 
becomes a priority; especially within the context of a hospitalized population, where S. 
aureus infection is a common cause of comorbidity.     
 For these reasons we wanted to investigate the role of MCP-1 in pulmonary innate 
immune responses in S. aureus pneumonia and hypothesized that MCP-1 would impart a 
protective response.  C57Bl/6, MCP-1-/- and MCP-1 AB blocked mice were infected intra-
tracheally with S. aureus strain USA300 followed by analysis of local and disseminated 
bacterial burden, pro-inflammatory cytokine, chemokine and pulmonary leukocyte 
recruitment profiles, and lung histopathology. 
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CHAPTER 2 
THE ROLE OF NOD-LIKE-RECEPTORS IN THE PULMONARY SYSTEM 
 
2.1. Abstract  
 Innate immunity is the first line of defense against microbes and as such innate 
responses to infectious stimuli frequently dictate outcomes including survival. Whereas Toll-
like receptors have been extensively studied and their importance in pathogen detection and 
clearance well documented, the importance of NOD-like receptor (NLR) family members is 
emerging.  The lung contains resident immune cells such as leukocytes and epithelial cells 
and is physiologically positioned to have constant and close contact with inhaled irritants and 
invading microbial pathogens. As bacterial lung infections are a significant cause of world-
wide mortality and innate immune responses often dictate survival from lung infections, 
understanding the role of NLRs in the pulmonary system is of particular importance.  This 
review highlights recent advances in our understanding of NLR family members, with 
specific focus on how these proteins sense and respond to pathogens and host-derived 
substances during respiratory bacterial infections. 
2.2. Introduction 
 The respiratory tract provides a unique microenvironment in which to explore the 
complex interplay between host immune responses and exogenous stressors such as microbes 
and environmental irritants is manifest. To be effective, respiratory immune responses must 
be sensitive, rapid, and diverse; these requirements are driven by constant contact with both 
commensal and pathogenic microbes and inhaled irritants such as smoke (e.g cigarette, 
biomass burning) that may possess immuno-modulatory properties. Globally, bacterial 
pneumonia represents an enormous burden of illness and is associated with substantial 
morbidity and mortality and the expenditure of significant economic resources. In the last 
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decade, the role of specific innate immune proteins in protecting the lungs from devastating 
infections such as bacterial pneumonia has been widely investigated. The availability of 
resources including specific gene-deficient mice has been a major driving force in this effort. 
However, the regulation of immune responses during bacterial infection that eventually 
contribute to host resistance has not been fully delineated. In this review, we focus on recent 
advances in understanding the importance of NOD-like receptors (NLRs) in orchestrating the 
innate immune response to bacterial infection.  
2.3. Bacterial pneumonia 
 Pneumonia is an infection of lung parenchyma, usually with bacteria. Bacterial 
pneumonia is common; in the United States, the incidence of bacterial pneumonia is 4 
million adults per year. Moreover, bacterial pneumonia is responsible for significant 
morbidity and mortality, accounting for 1.1 million hospitalizations, and 50,000 deaths per 
year.28 In fact, despite treatment with antibiotics and supportive measures, bacterial 
pneumonia remains the most common infectious cause of death in the U.S. Bacterial 
pneumonia is characterized clinically by the acute onset of productive cough, fever, and 
shortness of breath. Severe cases may progress to sepsis and respiratory failure requiring 
mechanical ventilation. The diagnosis is confirmed by radiographic imaging. 
 Although the lungs are constantly exposed to inhaled pathogens, a sophisticated host 
defense system is usually highly effective in the killing and clearance of microorganisms. In 
the event of exposure to a high burden or high virulence of pathogens or in the setting of a 
susceptible host, clinical pneumonia can develop. Certain bacteria have developed 
sophisticated virulence factors to evade a normal host defense system; host characteristics 
such as underlying structural lung disease, advanced age, and immunocompromised states 
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such as HIV, chemotherapy, and chronic steroid use predispose to pneumonia. The most 
common pathogens responsible for bacterial pneumonia are Streptococcus pneumoniae, 
Haemophilus influenzae, group A streptococci, Moraxella catarrhalis, Staphylococcus 
aureus, anaerobes, and aerobic Gram-negative enteric bacilli such as Escherichia coli, 
Legionella spp., Mycoplasma pneumoniae, and Chlamydophila pneumoniae.  
 In response to bacterial infection, sentinel cells such as macrophages become 
activated and secrete chemokines, which induce neutrophil migration into the lungs. 
Neutrophils clear bacteria by phagocytosis followed by killing via proteases and reactive 
oxygen species. Both the activation of sentinel cells and the phagocytosis and killing by 
neutrophils are critically dependent on the recognition of pathogens by the innate immune 
system.29 
2.4. Host defense 
 The innate immune response, the first line of defense against invading pathogens, is 
initiated when pattern recognition receptors (PRRs) on the surface or in the cytosol of 
sentinel immune cells sense pathogen-associated molecular patterns (PAMPs) in their 
vicinity. Following the interaction of PAMPs with PRRs, downstream signaling cascades are 
activated leading to increased production of cytokines and chemokines that promote 
recruitment of professional phagocytes and antigen-presenting cells to the site of infection 
and/or tissue injury. Four major groups of PRRs have been identified: Toll-like receptors 
(TLRs), Nucleotide recognition domain (NOD)-like receptors (NLRs), RIG (retinoic acid 
inducible gene)-1-like receptors (RLRs) and lectin receptors. The PAMP ligands for specific 
PRRs are highly conserved “non-self” molecular motifs of microbial origin; examples 
include lipopolysaccharide (LPS), peptidoglycan (PGN), flagellin, and CpG nucleotides. As 
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these motifs are common to both pathogenic and commensal microbes, PAMPs may be 
regarded as a misnomer for which a more inclusive acronym MAMP (microbe-associated 
molecular patterns) has been proposed.30 PRRs can also interact with another set of 
molecular motifs known as damage (or danger) associated molecular patterns which are 
endogenous (“self”) molecules emanating from stressed (dying/infected/neoplastic) cells.  
2.5. The NLR family 
 The NLR family consists of 22 members in humans, with protein orthologs in both 
vertebrates and invertebrates.31 NLRs are critical to the innate immune response. Unlike the 
transmembrane TLRs that detect either extracellular or endosomal ligands, NLRs exclusively 
sense cytosolic ligands.32 All NLR family members are characterized by a tripartite domain 
structure with C terminal leucine rich repeat (LRR) domain, a central NACHT (NAIP, CIIA, 
HET-E, TP1) /NOD domain and a variable N-terminal effector domain.33 NLRs are classified 
into 4 sub-families based on the N-terminal effector domain they contain: NLRA members 
have transactivator domains (AD); NLRBs have BIR (baculoviral inhibitor of apoptosis 
repeat) domains; NLRCs have CARD (caspase activation/ recruitment domains), and NLRPs 
have PYD (PYRIN domains) 31,34 (Figure 1). Each domain of the NLR molecule has a unique 
function. The C terminal LRR sensing domain recognizes and binds to a variety of cytosolic 
ligands.  This is followed by oligomerization of NACHT domains, a crucial but incompletely 
understood step. Oligomerization leads to the formation of an N-terminal platform where 
diverse adaptor molecules and downstream effectors may bind.31,34 The variable molecular 
makeup at the N terminus ascribes a degree of structural heterogeneity that is utilized during 
activation of diverse signaling pathways depending on the specificity of NLR and/or their 
ligands (Figure 2).   
! 10 !
 
 
 
Figure 1. A schematic comparing molecular structures of different NLR family members. All 
NLR family members have a tri-partite domain organization comprising of C-terminal LRR, 
middle NACHT and a variable N-terminal domain. The variability of N-terminal domains is 
the basis for the division of NLRs into distinct subgroups.  
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Figure 2. A schematic representation of NLR signaling pathways. Various PAMPs ligands 
that bind cytosolic NLRs and activate downstream pro-inflammatory signaling pathways in 
the respiratory tract are indicated.    
 
The NLR ligands range from bacterial and viral components to particulate matter and 
crystals.  For intracellular pathogens and pathogens equipped with trans-membrane secretion 
systems (e.g., the type III secretion system of Pseudomonas aeruginosa and Dot/Icm type IV 
secretion system of Legionella pneumophila (Lp) 35,36), the PAMPs are delivered to the 
cytosol. Recent work demonstrates that extracellular Gram-negative bacteria can shed outer 
membrane vacuoles or “blebs” containing bacterial products  that can be transported by lipid 
rafts to the cytosol of non-phagocytic cells for interaction with the NOD1 NLRs.37 Apart 
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from these examples, the exact molecular mechanism(s) for transport of the majority of NLR 
ligands across the host cell membrane remains elusive.  
2.6. NOD1/NOD2 signaling 
 The cytosolic proteins NOD1 and NOD2 contain CARD domains at their N-termini. 
While NOD1 is expressed in a wide variety of cells and tissues, NOD2 is expressed in  
relatively few cell types including macrophages, dendritic cells, keratinocytes, and lung and 
intestinal epithelium.31 Principally described ligands for NOD receptors are components of 
bacterial peptidoglycan. Specifically, m-DAP (L-Ala-γ -D-Glu-m-diaminopimelic acid) 
found in most Gram-negative and some Gram-positive bacteria binds NOD1while the MDP 
(muramyl dipeptide) motif present in the peptidoglycans of both Gram-positive and Gram-
negative bacteria binds NOD2 LRR.31 Peptidoglycan binding is followed by oligomerization 
of the central NACHT domains and recruitment of the cytosolic adaptor molecule receptor 
interacting protein 2 (RIP2 at the N-terminus by CARD-CARD interaction. RIP2 is then 
ubiquitinated, leading to the activation of downstream NF-κB signaling and upregulation of 
genes involved in host defense and apoptosis (Figure 2).15,31,38,39 In certain infection models, 
membrane localization of the NOD-RIP2 complex is a prerequisite for activation of NF-κB 
signaling 40 For example, the respiratory syncytial virus (RSV) induces the NOD2-RIP2 
complex to bind the adaptor MAVS (mitochondrial viral signaling) on the mitochondrial 
membrane 41, while the Shigella flexneri induced the NOD1-RIP2 complex to bind to the 
host plasma membrane.40  
2.7. Role of NOD receptors in bacterial pneumonia 
 The importance of NOD receptors in pulmonary defense is highlighted by studies 
using murine models of bacterial pneumonia. In comparison with their WT counterparts, 
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mice deficient in specific NOD receptors (NOD1-/- or NOD2-/-) or RIP2 (RIP2-/- , which  are 
functionally equivalent to NOD1-/-/NOD2-/- double knockouts) consistently show reduced 
levels of pulmonary cytokines and chemokines accompanied by reduced inflammation and 
impaired neutrophil recruitment to the lungs following infection with Escherichia coli 38, 
Staphylococcus aureus 15 or Chlamydophila pneumoniae 39. In contrast, results from 
pulmonary bacterial burden assays are not as consistent. NOD2-/- mice exhibit reduced 
neutrophil killing and hence increased bacterial burdens following infection with E. coli. 38 
Similar results (impaired cytokine/chemokine expression, delayed neutrophil recruitment and 
bacterial clearance) are observed when RIP2-/- , NOD1-/-, and NOD2-/- deficient mice are 
infected with C. pneumonia. 39  Surprisingly, in NOD2-/- mice infected with S. aureus, 
reduced pulmonary neutrophils counts are accompanied by reduced bacterial CFUs.15 
Similarly, in murine models of Legionella pneumonia, NOD1-/-, NOD2-/-  and RIP2-/- mice 
show impaired neutrophil recruitment compared to WT mice, although a small increase in 
bacterial CFUs was observed only in the lungs of RIP2-/-mice.35 These results suggest a 
possible co-operation between NOD1 and NOD 2 receptors in mediating Legionella-induced 
activation of RIP2. Taken together, these observations firmly establish NOD receptors at the 
crossroads of bacterial PAMP identification, pro-inflammatory pathways and neutrophil 
recruitment. Their importance in resolution of infection by promoting bacterial clearance 
varies with specific pathogens. 
 In addition to the well-documented role of NOD receptors in neutrophil recruitment, 
NOD1/NOD2 signaling also contributes to the production of soluble anti-bacterial and anti-
viral molecules. Synthetic PAMPs have been shown to induce human oropharyngeal 
epithelial cells to produce the antibacterial molecule β-defensin 2 in an NF-κB dependent 
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manner in vitro.42 NOD2 is also involved in induction of type I interferon (IFN) in response 
to intraphagosomal Mycobacterium tuberculosis in murine macrophages 43 and also in 
response to RSV ssRNA, a non-peptidoglycan PAMP.41   
2.8. NLR inflammasomes  
 Upon ligand binding, NLR proteins NLRC4, NLRP1, and NLRP3 form distinct 
hetero-oligomeric structures known as inflammasomes, which are platforms for the 
recruitment of pro-caspase1 zymogen by CARD-CARD interaction followed by activation by 
proteolytic cleavage. Caspase 1 protease in turn activates pro-IL1β and pro-IL-18 to IL1β 
and IL-18 respectively inducing inflammation and/or cell death, a process termed 
‘pyroptosis’. The CARD in an inflammasome may belong to either a constituent NLR such 
as NLRC4 (NLR family, CARD domain containing 4), or alternatively, to a CARD 
containing adaptor protein ASC (apoptosis-associated speck like protein containing a CARD 
1) recruited by a homotypic PYD interaction between ASC and NLRP1 or NLRP3.34,44 The 
molecular components of different inflammasomes, downstream signaling cascades, and 
their relevance to bacterial pneumonia will be discussed below.  
2.9. NLRC4 and NAIPs 
 NLRC4 and NAIP (NLR family apoptosis inducing protein) are two structurally 
dissimilar NLR proteins that form inflammasomes following activation by two bacterial 
PAMP ligands, flagellin, and the type III secretion system needle apparatus constituent 
protein PrgJ.44,45 Similar to NOD1/NOD2, NLRC4 consists of an N terminal CARD (Figure 
1), although oligomerization of the central NACHT/NOD domains by NLRC4 proteins 
results in the formation of an inflammasome (Figure 2).44 The concept of the NAIP-NLRC4 
inflammasome originates in observations that the macrophages from A/J mice are highly 
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permissive to Legionella replication in comparison to macrophages from other mouse strains 
such as C57BL/6, Balb/C and C3H/HeN.46 This phenotypic difference was subsequently 
mapped to the presence of a chromosome 13 locus containing a family of Naip (neuronal 
apoptotic inhibitory protein) genes in non-permissive mouse strains.44,46 Today we know that 
there are four Naip paralogs in mice  (i. e. Naip1, Naip2, Naip5, and Naip6), while only one 
functional protein, NAIP, has been detected in humans.44,47  Polymorphism of the Naip5 gene 
in A/J mice has been implicated in their relative susceptibility to Legionella,  based on the 
observation that  Naip5-/- mice  in a C57/BL6 background are highly susceptible to Lp.48  
Similarly, the replication of Lp in human macrophages which precedes the development of 
Legionarre’s disease in people, is likely explained by the lack of human Naip to respond to 
bacterial flagellin.45 
Naips exhibit tripartite protein structure with C-terminal LRR, middle NBD and N-
terminal BIR domain akin to other NLR family members. Three tandem repeats of BIR at the 
N-terminus is a feature that Naips share with members of the apoptosis inhibitory protein 
(AIP) family (Figure 1), although most experimental evidence indicates that the primary role 
of Naips is in the regulation of innate immunity rather than apoptosis.44 Naip5 and NLRC4 
functionally complement one another as inflammasome constituents with Naip-LRR acting 
as a PAMP sensor while NLRC4-CARD recruits and activates pro-casapse1 by CARD-
CARD interaction. The role of the BIR domains in the organization of inflammasomes, their 
downstream signaling and their relevance to immune defense against bacterial pathogens 
remains to be elucidated, although it is proposed that all three BIR domains are necessary for 
PAMP-induced oligomerization of NLRC4.49 
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In the case of Legionella, murine Naip5 and human NAIP act as cytosolic sensors that 
oligomerize with NLRC4 in response to flagellin. While the molecular mechanism leading to 
inflammasome assembly remains nebulous, the NLRC4-Naip interaction has been fairly 
well-defined.44 In contrast, the concept of NLRC4-Naip functional complementarity is well-
established. As Naip5 lacks CARD, it is structurally incapable of recruiting and activating 
caspase1 by itself. Thus NLRC4-/- mice are defective in mounting an inflammaory response 
to cytosolic flagellin from Salmonella typhimurium.44,50 Also, macrophages from Naip5-/- 
mice fail to activate caspase-1 and IL-1β and do not undergo pyroptotic death in response to 
Legionella.48 Additional biochemical evidence further strengthens this concept: constitutively 
active NAIP5ΔLRR induces oligomerization of NLRC4, a step necessary for production of 
Caspase-1 even in the absence of flagellin ligand, while constitutively active NLRC4ΔLRR 
activates caspase-1 even in absence of NAIP5.49 The dispensability of Naip5, as observed in 
certain models of NLRC4 inflammasome activation, spearheaded the investigation of other 
Naips as potential cytosolic sensors involved in ligand binding. Naip paralogs are proposed 
to be involved in differential ligand recognition. For example, Naip5 LRR (and to some 
extent Naip6 LRR) selectively recognizes flagellin, Naip2 LRR recognizes PrgJ (T3SS 
needle protein) while Naip1 is an orphan member with an unknown PAMP ligand.45,49   
These observations clearly establish Naips as cytosolic sensors of different PAMPs that act 
upstream of NLRC4 effectors.  
A recent publication has documented that both murine and human macrophages 
respond to Klebsiella pneumoniae via NLRC4 activation, and that NLRC4 activation is 
critical for development of protective immunity in a murine in vivo model.51  Further studies 
are needed to determine the importance of NLRC4 in innate immune responses to other 
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relevant pulmonary pathogens, including both murine models and human cell lines, given the 
dissimilarities present in NAIP expression between mice and humans.  
Since NLRC4 is equipped with its own CARD domain, whether the ASC adaptor is 
necessary for NLRC4 inflammasome function is not fully established 44.  Legionella activates 
two independent pathways of caspase1 activation via induction of ASC or NLRC4-NAIP 
inflammasomes.52 Ligands and upstream effectors of ASC-dependent pathway are unknown. 
Activation of both pathways is required for maximal production of IL1β and IL18 although 
NLRC4-NAIP-mediated pyroptosis is independent of ASC activity.52 Based on more recent 
microscopic evidence, ASC appears to be involved in spatial sequestration of NLRC4 -
caspase1 complexes.53 This suggests convergence of these two pathways at a centralized 
ASC platform which may help in maintaining a delicate balance between two caspase 1-
induced downstream processes; pyroptosis and proinflammatory cytokine release. 
2.10. NLRP1 
 NLRP1 is structurally distinct from other NLRs in that it has two signal transduction 
domains; PYD at the N-terminus and CARD at the C-terminus. The LRR domain is 
positioned between PYD and the central NOD (Figure 1). It is proposed that the C-terminal 
CARD binds caspase 5 while the N-terminal PYD homotypically binds PYD of ASC. ASC is 
a bipartite adaptor that in turn contributes CARD for recruitment and induction of pro 
caspase-1.34,54 The NLRP1 inflammasome platform composed of CARD8, ASC, caspase-5, 
and caspase-1 was first described in a cell-free system.34,55 It has been suggested that the 
activities of both caspase 1 and 5 are necessary for NLRP1 inflammasome mediated IL1β 
maturation.34,55 Biochemical evidence suggests that NLRP1 inflammasome activation is a 
two-step process. In the first step, bacterial MDP PAMP binds NLRP1 LRR and primes the 
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central NACHT domain for NTP binding leading to the second step of NLRP1 
oligomerization and procaspase-1 recruitment. ASC may augment the function of NLRP1 but 
is not required for inflammasome function, as NLRP1 equipped with C-terminal CARD may 
interact with procaspase-1 bypassing the requirement of ASC.34,56   
Unlike humans with a single functional nlrp1 gene, the murine genome encodes three 
highly homologous, tandem paralogs; nrlp1a, nlrp1b, nlrp1c. Nlrp1b is a highly polymorphic 
paralog that is activated by proteolytic cleavage mediated by Bacillus anthracis virulence 
factor, anthrax lethal toxin.57 This leads to caspase1 activation which is the molecular event 
that determines strain-specific susceptibility of murine macrophages to anthrax lethal 
toxin.34,58 Activation of NLRP1 by anthrax lethal toxin has been shown to result in 
irreversible acute lung injury that is dependent on caspase1 activation and not on IL1β 
maturation. In contrast, the ligand for highly conserved NLRP1a is undefined 59, while the 
NLRP1c is a truncated protein with unknown relevance to inflammasome assembly/function. 
Notably, anthrax lethal toxin does not activate human NLRP1.  Although the role of NLRP1 
in human health and disease remains elusive, the interaction of murine NLRP1 and LT 
illustrates that NLR activation can be responsible for significant end organ damage.   
2.11. NLRP3 
 The defining feature of NLRP3 (NLR family; PYD containing 3) is the N terminal 
PYD (Figure 1) that homotypically binds PYD of ASC. The NLRP3 inflammasome is 
prototypical in its requirement for two distinct signals for activation. The pre-assembly 
“priming” signal comes from TLR activation that induces NLRP3 expression via NF-κB 
activation. Once the cytosolic amount of NLRP3 reaches a threshold, inflammasome 
assembly is initiated in response to a second signal in the form of one or more of NLRP3 
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ligands.60 The two signal process may act as a cellular safeguard against hyper-activation of 
the NLRP3 inflammasome. NLRP3 ligands are a curiously heterogeneous group of 
compounds ranging from exogenous materials such as bacterial PAMPs, ozone, asbestos, 
silicon and particulate matter to endogenous alarmins such as uric acid from DNA damage, 
ATP and mitochondrial contents.61-66 Hyperactivation of NLRP3 resulting in increased 
accumulation of pro-inflammatory cytokines such as IL1β is involved in the pathogenesis of 
pulmonary fibrosis.67,68 The ability of the NLRP3 inflammasome to respond to an array of 
structurally and chemically diverse signals points to convergence on a common sub-cellular 
signaling event upstream of inflammasome assembly. Presently, three signaling pathways 
have been proposed to be involved in these processes: ROS (reactive oxygen species), 
intracellular electrolyte shift (K+ efflux), and lysosomal disruption.69-71 Needless to say, each 
of these models has limitations. ROS production may qualify as the common upstream 
signaling effector based on the observations that ‘frustrated phagocytosis’ of large crystals 
(e.g.; asbestos) activates mitochondrial NADPH oxidase (NOX) and that NLRP3 
inflammasome assembly is affected by ROS inhibitors.65,72 Recently, Bauernfiend et al have 
suggested that ROS activation is an important upstream event required for the priming of 
NLRP3 inflammasome formation.69 Large crystal phagocytosis is also implicated in 
lysosomal rupture, release of lysosomal protein cathepsin B in the cytosol and subsequent 
activation of NLRP3 based on the observation that cathepsin B inhibitors abrogate crystal-
mediated NLRP3 inflammasome activation while artificial lysosomal disruption (mediated 
by osmolarity alterations) activates NLRP3 inflammasome.71  ATP mediated potassium 
efflux and calcium influx activates ion channel function of purinergic receptor P2X7 also 
resulting in the activation of the NLRP3 inflammasome.70  Conversely, the presence of high 
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K+ containing buffers blocks NlRP3 inflammasomes.66  Pore formation by P2X7-activated 
Pannexin or by the activity of microbial toxins activates the NLRP3 inflammasome.73 
Bacterial pore-forming toxins (PFTs) such as streptolysin O (Streptococcus pyogenes), alpha-
hemolysin (S. aureus), and hemolytic pneumolysin (ply, Streptococcus pneumoniae) are 
particularly relevant virulence factors involved in the pathophysiology of bacterial 
pneumonia and are established as inducers of NLRP3 inflammasomes.61-63,74,75 The 
variability of PFT expression among bacterial strains in part dictates the immunologic 
response generated.  For instance S. pneumoniae strains producing non-hemolytic variants of 
ply are capable of establishing infection without activating IL-1β production via NLRP3.62 
Whether the membrane channels/pores induce K+ efflux or function as trans-membrane 
gateways facilitating entry of ligands into the cytosol allowing for direct interaction with 
NLRP3 is not clear.  
 What is apparent, is that NLRP3, through cross-talk with TLRs, and ability to 
recognize diverse ligands, may play a crucial role in pulmonary immunity. The inflammation 
resulting from NLRP3 activation may facilitate clearance of pneumococci producing 
hemolytic pneumolysin, or it may abrogate replication of the atypical mycobacterial 
pathogen M. kanasii in human macrophages.61,76 In other instances, such as asbestosis and 
silicosis, NLRP3 activation is deleterious as it promotes chronic inflammation and fibrosis.72  
Furthermore, its ability to sense and respond to endogenous alarmins that leak from necrotic 
cells, indicates it could be activated downstream of any pulmonary condition that induces 
necrosis.63      
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2.12. NLRP6 and NLRP12 
 The newly recognized NLRP6 and NLRP12 are inflammasome-forming NLRs that 
oligomerize with ASC, although details about the downstream signaling pathways are 
lacking.77-80  However, in this context the term inflammasome may be a misnomer, as 
NLRP6 and NLRP12 may induce anti-inflammatory immune responses.  Detection of high 
levels of nlrp6 transcripts in neutrophils, T cells, macrophages and epithelial cells 81 suggests 
that NLRP6 may be relevant in the immune defense of respiratory tract and other organs. 
NLRP6 -/- mice display reduced IL-18 levels and colonic dysbiosis (alteration in the structure 
of normal intestinal microflora) leading to inflammatory colitis.77,78 NLRP6 is dispensable 
for Listeria monocytogenes induced neutrophil IL-1β release.82 Moreover, in a mouse model 
of infection with Listeria, NLRP6-/- mice have a survival advantage over their WT 
counterparts and show increased levels of circulating levels of neutrophils and macrophages 
accompanied by increased clearance of bacteria from liver and spleen.  Whether NLRP6 
suppresses innate immune function in response to other bacterial pathogens is unknown.83 
NLRP12 is a prototypical member of anti-inflammatory NLRs; it is exclusively produced by 
eosinophils, granulocytes and monocytes and it is an established negative regulator of the 
non-canonical pathway of NF-κB activation.80,84 NLRP12 suppresses IL1β and IL18 
production (and IFNγ production via IL18) mediated by Yersinia pestis 79 although no 
differences were observed in survival profiles, disease progression, and host response 
mounted by NLRP12 -/- and WT mice after airway exposure to M. tuberculosis or K. 
pneumonia.85 
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2.13. Perspective 
 With the rapidly expanding knowledge of innate immune responses at the molecular 
level, a more comprehensive approach is needed to link seemingly unrelated molecular 
effectors and parallel signaling pathways in relation to one another is urgent. This will not 
only generate comprehensive maps of intricate molecular mechanisms of innate immune 
responses to invading pathogens, but identifynovel targets  for future therapeutic 
interventions.  Discovery of inflammasomes, and the description of crosstalk between TLRs 
and NLRs to generate proinflammatory cytoking responses, represent the initial steps 
towards a more complete understanding 86 It is evident that the specificity between 
interacting PRRs and PAMP ligands is not exclusive, and that activation of a particular PRR 
may lead to the simultaneous induction of different signaling pathways.87 Despite these 
major discoveries , many crucial questions remain unanswered, including 1) What are the 
PAMP ligands activating inflammasomes such as NLRP4 and NLRC4?; 2) How are the 
molecular patterns of extracellular pathogens transported across the cytoplasmic membrane?; 
3) What factors determine whether activation of inflammasome pathways result in an 
inflammatory response or cell death? A better understanding of interplay between different 
PRRs in response to a pathogenic insult will pave the way for more sophisticated therapies 
for a number of infectious, autoimmune, and neoplastic diseases in the lung and other organs. 
 
  
 
 
 
 
 
 
 
! 23 !
CHAPTER 3  
LITERATURE REVIEW 
 
3.1. Innate immunity in bacterial pneumonia 
 Innate immunity is the body’s first line defense system, and consists of molecular 
sensors and effectors that are activated in response to invading pathogens or endogenous 
signals. Cellular components of innate immunity  include surface epithelium and leukocytes 
such as  histiocytes (macrophages and dendritic cells), neutrophils, natural killer cells, mast 
cells, eosinophils and basophils.  A wide array of intracellular and extracellular proteins 
assist in innate immunity including soluble and cell associated pattern recognition receptors, 
enzymes capable of hydrolyzing cell wall components or creating toxic oxygen/nitrogen 
compounds, as well as constituents of the complement cascade and acute phase response.22 
The ways in which cells sense invading microbes, the signaling cascades which occur 
downstream of pathogen recognition, and the antimicrobial properties of various innate 
immune effectors are outlined below, with particular focus on those central to bacterial 
clearance in pneumonia. 
3.1.1. Cellular effectors 
3.1.1.a. Neutrophils 
 Neutrophils are short-lived bone marrow derived granulocytic cells that provide the 
first line of defense against many invading microbes.  Neutrophils are professional 
phagocytic cells that contain granules replete with bactericidal substances.  The 
primary/azurophilic granules in neutrophils contain myeloperoxidase (MPO), other 
proteolytic enzymes (cathepsins, elastase), and defensins.1  Secondary/specific granules, so 
called as they develop second in neutrophil maturation, contain important membrane proteins 
including lactoferrin and collagenase as well as receptors for chemotactic molecules, 
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cytokines, opsonins, and extracellular matrix proteins.  In health, murine neutrophils circulate 
for 10-24hrs before entering tissues where senescent neutrophils become apoptotic and are 
engulfed by macrophages.1  During inflammation, microbe and host-derived signals initiate 
immune cascades resulting in production of neutrophil chemotactic molecules (i.e. IL-8, G-
CSF) which can bind to receptors on neutrophils initiating chemotaxis towards sites of 
inflammation, while altering expression of integrins on endothelial cells to promote 
neutrophil extravasation into tissues. 
 Neutrophils are equipped with cell associated pattern recognition receptors (PRRs) 
including Toll-like receptors (TLRs) and Nod-like receptors (NLRs).  PRRs recognize highly 
conserved motifs of pathogens, known as pathogen associated molecular patterns (PAMPs) 
as well as substances (i.e. mitochondrial DNA, heat shock proteins) liberated from stressed or 
dying host cells, known as danger associated molecular patterns (DAMPs).  Activation of the 
cell-associated PRRs by PAMPs/DAMPs in neutrophils initiates intracellular signaling 
cascades resulting in neutrophil phagocytosis, degranulation, reactive oxygen species 
production, and cytokine/chemokine generation.1  Additionally neutrophils have receptors for 
soluble PRRs such as collectins, as well as complement, both of which enhance phagocytosis 
of bacteria via opsonization. 
 Once bacteria are inside neutrophil phagosomes, the contents of primary and 
secondary granules can fuse with the phagosome, exposing organisms to bactericidal 
products including oxygen dependent (i.e. ROS, superoxide, MPO) and independent (i.e anti-
microbial peptides, elastase, lactoferrin) substances.1  A more recently identified means of 
neutrophil-mediated microbe killing is via formation of neutrophil extracellular traps (NETs).  
NETs are comprised of chromatin, histones, azurophilic granules and cytosolic proteins with 
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bactericidal activity demonstrated against a variety of pathogens including S. aureus.  It 
appears that generation of ROS is a prerequisite in some experimental models for NET 
formation, however whether NETs constitute a unique form of cell death, or are cast from 
live cells is still an issue of debate.1 
 Neutrophil apoptosis is a form of anti-inflammatory cell death that occurs both in 
healthy cells as a natural regulator of neutrophil numbers, and in states of 
inflammation/infection.  While the mechanisms governing neutrophil apoptosis differ in 
health and disease, the net result is caspase-mediated cleavage of nuclear contents, 
preservation of the cell membrane (preventing liberation of highly inflammatory neutrophil 
products into the extracellular space) and exposure of phosphatidylserine (PS) onto the 
extracellular lipid bilayer.  PS acts as a signal for macrophages to engulf these senescent cells 
(efferocytosis).  In addition to freeing the extracellular space of the many toxic products 
present within neutrophils, the action of efferocytosis by macrophages causes these 
professional phagocytes to produce the anti-inflammatory cytokines IL-10 and TGF-β, 
further contributing to resolution of inflammation.1 
3.1.1.b. Alveolar macrophages 
 Alveolar macrophages (AMs) are specialized macrophages that reside in the alveoli.  
Studies support both monocyte and pulmonary derived sources of AMs.  Studies in mice 
estimate 15% of blood monocytes migrate to the lungs to replace AMs.  However maturation 
of AMs from pulmonary cells of intermediate differentiation has also been demonstrated.13  
Alveolar macrophages respond to invading pathogens by both phagocytosis and immune 
signaling via PRRs.  Phagocytosis is mediated by binding of opsonized or non-opsonized 
microbes to a plethora of receptors.  Within macrophages nitric oxide is produced via 
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inducible nitric oxide synthase.  Theorized to perhaps protect the lung tissue in their 
surrounding specialized micro-environment, AMs in humans produce NO to a lesser extent 
than inflammatory macrophages in other tissues and also have efficient anti-oxidant 
mechanisms.13  While these cells are professional phagocytes, their ability to ingest 
pathogens is ultimately limited.  In addition to phagocytosis, sensing of microbial PAMPs by 
AMs occurs via PRRs (TLRs and NLRs).  These signaling cascades not only enhance 
microbe killing and phagocytosis by AMs but also recruit neutrophils to the airways. 
3.1.1.c. Epithelial cells 
 A heterogenous population of epithelial cells exists from the trachea to the alveoli 
including basal cells, secretory and ciliated epithelial cells, neuroendocrine cells and type I 
and type II alveolar pneumocytes.95  The production of mucus and movement of cilia serve to 
trap inhaled irritants and microbes and propel them back towards the oropharynx.  Surfactant 
proteins A and D produced by type II alveolar pneumocytes are anti-bacterial collectins.13  In 
addition to these constitutive anti-bacterial functions, epithelial cells are able to initiate 
immune responses via pathogen sensing and subsequent pro-inflammatory signaling 
cascades.  As previously mentioned, NFκ-B is an important transcription factor in pro-
inflammatory signaling.  In pneumonia models where NFκ-B was selectively blocked in 
alveolar epithelial cells, generation of cytokines and chemokines and degree of inflammatory 
cell infiltrate after pathogen challenge were severely blunted.13  In separate experiments 
using mice deficient in the TLR adaptor MYD88, it was shown that the NF-κB mediated 
signaling was reestablished after selectively restoring MyD88 function to alveolar epithelial 
cells, suggesting TLRs are central to NFκ-B cascades generated in epithleial cells.13   
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 Another transcription factor important in epithelial cell response in pneumonia is 
STAT3.  Unlike NFκ-B, STAT3 activation does not appear to occur via PAMP/PRR 
interactions on epithelial cells, but rather via cross talk between epithelial cells and resident 
leukocytes.  The importance of STAT3 in pulmonary immunity is obvious in the naturally 
occurring human disorder hyperimmunoglobulin E syndrome (HIES) in which patients have 
severely decreased levels of STAT3.  While all cells in the body are deficient in STAT3 
expression, the clinical course of this disease is typified by recurrent pulmonary infections, 
often beginning early in childhood, with pneumonia being the major cause of death in these 
patients.13  Increased susceptibility to pneumonia in these patients may involve epithelial 
cells directly and indirectly.  STAT3 is activated downstream of IL-6 and IL-23 and is vital 
in differentiation of TH17 T cells.  TH17 cytokines (IL-17, IL-22) play important roles in 
pulmonary immunity, some of which is achieved via signaling with epithelial cells and 
inducing these cells to produce β-defensins and CXC chemokines.13 However, selectively 
blocking STAT3 in T cells fails to recapitulate the HIES phenotype.13  When STAT3 was 
selectively blocked in the alveolar epithelial cells of mice, animals had more severe lung 
injury as compared to WT controls, the degree of which did not correlate with neutrophil 
recruitment between the groups, suggesting a role for STAT3 in maintaining epithelial cell 
health independent of inflammatory signaling.13 
3.1.2. Pattern recognition receptors 
 Pattern recognition receptors (PRRs) are cell associated or secreted molecules that 
recognize “non-self” signals known as pathogen-associated molecular patterns (PAMPs) 
including bacterial and viral components or endogenous danger associated molecular patterns 
(DAMPs) such as mitochondrial DNA and heat shock proteins liberated from dying cells.  
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Some cell associated PRRs, including CD14 and C-type lectin receptors, are endocytic 
receptors that initiate internalization and phagocytosis of pathogens upon PAMP binding.  
Similarly soluble PRRs including collectins and ficolins opsonize pathogens, tagging them 
for phagocytosis, and also aid in complement associated killing.14  In contrast the cell 
associated Toll-like receptors (TLRs) and NOD-like receptors (NLRs) initiate intracellular 
signaling cascades upon PAMP binding, which culminate in pro-inflammatory chemokine 
and cytokine production, and in some instances, programmed cell death. 
 The TLR family includes unique transmembrane receptors expressed by a wide 
variety of cells such as lymphocytes, histiocytes, epithelial cells, endothelial cells, and 
fibroblasts, which vary slightly in number across mammalian species (i.e. 12 murine TLRs 
and 10 human TLRs).13  Cell membrane associated TLRs (TLR 1,2,4,5,6) sense an array of 
peptides and lipopeptides including bacterial cell wall components and flagellin, whereas 
endosomal TLRs (3,7,9) sense nucleic acids.14  These receptors are comprised of PRR 
sensing C terminal leucine rich repeats (LRR), a trasmembrane domain, and a N terminal toll 
and interleukin receptor (TIR) which associates with downstream adaptor proteins (most 
importantly MyD88) to initiate intracellular signaling.  The TLR signaling cascade leads to 
NFκ-B and MAP kinase activation culminating in increased production of inflammatory 
cytokines such as TNF-α and IL-6 and neutrophil and monocyte chemotactic molecules such 
as IL-8 and MCP-1 (Figure 3).14  
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 NLRs similarly display tripartite structure with a C terminal leucine rich repeat 
domain, a central NACHT (NAIP, CIIA, HET-E, TP133)/NOD domain and a variable N-
terminal effector domain.31  The NLR ligands range from bacterial and viral components, to 
particulate matter and crystals.  For the well studied NLRs such as NOD1/NOD2, ligands 
include components of bacterial peptidoglycan. Specifically, m-DAP (L-Ala-γ -D-Glu-m-
diaminopimelic acid) found in most Gram-negative and some Gram positive bacteria, is 
detected by NOD1while MDP (muramyl dipeptide) motif, ubiquitously present in the 
peptidoglycans of both Gram-positive and Gram-negative bacteria, is detected by NOD2 
LRR.31 PGN binding is followed by oligomerization of the central NACHT domains and 
recruitment of the cytosolic adaptor molecule RIP2 (receptor interacting protein 2) at the N-
terminus by CARD-CARD interaction. RIP2 is then ubiquitinated leading to the activation of 
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downstream NF-κB signaling and upregulation of genes involved in host defense and 
apoptosis (Figure 2).31 
 Upon ligand binding, some NLR proteins (NLRC4, NLRP1, and NLRP3) form 
distinct hetero-oligomeric structures known as inflammasomes which are platforms for the 
recruitmentof pro-caspase 1 zymogen followed by its activation to caspase 1 by proteolytic 
cleavage. Caspase 1 protease in turn activates pro-IL1β and pro-IL-18 to IL-1β and IL-18 
respectively, inducing inflammation and/or inflammatory cell death termed pyroptosis 
(Figure 3).65  Of the inflammasomes NLRP3 arguably has the most relevance to pulmonary 
pathology, as it is documented to respond to a curiously heterogenous group of compounds 
ranging from exogenous materials such as bacterial PAMPs, ozone, asbestos, silica and 
particulate matter to endogenous alarmins such as uric acid from DNA damage, ATP and 
mitochondrial contents.65,75   
3.1.3. Cytokines and chemokines 
 Cytokines are small soluble proteins secreted by immune (ie monocytes, dendritic 
cells, granulocytes, lymphocytes) and non-immune cells (fibroblasts, epithelial and 
endothelial cells).  Cytokines can be broadly grouped into five families based on 
functionality: interleukins, interferons, TNF ligands, growth factors, and chemokines.  Major 
cytokines and chemokines of interest at early time points in pulmonary innate immune 
responses to bacterial pathogens are described below.   
3.1.3.a. TNF-α 
 Part of the TNF super family, TNF-α is produced predominately by macrophages but 
is made by a wide array of other cells including neutrophils, mast cells, endothelial cells, 
fibroblasts, NK cells and CD4+ T cells in response to microbial products and cytokines such 
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as Il-1, IL-2, and interferon.96,97  The cell associated form of  TNF-α is released by the action 
of ADAM 17 (also termed TNF-α converting enzyme) in a homotrimer form, necessary for 
binding to its receptor.97  TNF-α induces endothelial cells to express neutrophil adhesion 
molecules (ICAM-1 and VCAM-1), augments immune cell function such as macrophage 
phagocytosis, cytokine secretion, release of reactive oxygen species, and provides positive 
feed back for NFκ-B activation to increase levels of pro-inflammatory cytokines.96  It also 
has distant effects that include crossing the blood brain barrier to interact with the 
hypothalamus to induce fever, and causing hepatocytes to upregulate the production of acute 
phase proteins such as protein C which enhances complement function.96 
3.1.3.b. IL-6  
 IL-6 is produced primarily by monocytes and macrophages in response to signaling 
via other cytokines (i.e. IL-1, TNF-α) or PAMPs (LPS, microbial nucleotides).  IL-6 binds its 
receptor (IL-6R) α chain and the signal transducing component gp130.97  It is the most 
important signaling molecule for induction of the acute phase response.  The acute phase 
response refers to the modulation of protein synthesis, which occurs in the liver upon 
stimulation with increased concentrations of cytokines such as IL-6, TNF-α and IL-1β.  
During times of inflammation the liver down regulates production of albumin (the major 
negative acute phase protein) presumably to use the amino acid precursors for formation of 
positive acute phase proteins (APPs).  There are many APPs with species specific relative 
importance but ultimately, regardless of species, the concerted function of these proteins is to 
enhance multiple facets of innate immunity including complement activation, opsonization, 
scavenging of free radicals, protease inhibition, and coagulation.98  Additionally IL-6 
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activates cytotoxic T cells and is involved in the differentiation of B cells into 
immunoglobulin producing plasma cells.97 
3.1.3.c. IL-1β and IL-18 
  IL-1β and IL-18 are both part of the IL-1 family.  These cytokines are unique in that 
they are synthesized in an inactive pro-enzyme form, requiring the activity of caspase-1 
generated by inflammasome assembly to be cleaved into their active forms.97  IL-1β is 
important in activating T-lymphocytes by enhancing production of IL-2 but also shares 
biological functions with both TNF-α and IL-6 including upregulation of leukocyte adhesion 
molecules (ie  ICAM-1, VCAM-1, E-selectin) on endothelial cells, and mediating systemic 
effects such as pyrexia and induction of the acute phase response.  The final steps in ICAM-1 
expression as mediated by IL-1 and TNF-α requires IL-18.  Along with IL-12, IL-18 is also 
an important inducer of INF-γ.97 
3.1.3.d. IL-17 
 The IL-17 family is comprised of 6 members (IL-17A through IL17F) which share 
virtually no sequence homology to other cytokines.  IL-17A is often referred to 
interchangeably as IL-17 and is primarily produced by a subset of CD4+ T cells (Th17 cells), 
with other possible cellular sources including neutrophils, eosinophils and CD8+ T cells.97  
Immune responses of IL-17A include induction of IL-6, IL-8, and granulocyte colony 
stimulating factor (GM-CSF) in cellular targets (ie fibroblasts, endothelial cells, epithelial 
cells) bearing the IL-17 receptor.97  Via its induction of IL-8 and G-CSF, IL-17 is an 
important player in neutrophil recruitment to the airways, however its effect on pulmonary 
immunity extend beyond leukocyte recruitment, as it can also induce goblet cell hyperplasia 
and increase mucus production by pulmonary epithelium.97 
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3.1.3.e. IL-8 
 While initially termed as an interleukin, IL-8 is also referred to interchangeably as 
CXCL-8, a more suitable nomenclature that denotes its major role as a chemokine, as well as 
its structure.  Chemokines are divided into four subclasses (CC, CXC, CX3, C) where C 
denotes the arrangement of cysteines within the molecule.99  CXC chemokines such as 
CXCL-8 have one intervening amino acid (ie X) between their cysteine residues.  IL-
8/CXCL-8 is a potent neutrophil chemoattractant produced by many cell types (i.e.  
leukocytes, endothelial cells, epithelial cells, fibroblasts) which binds to its receptors 
(CXCR1 and CXCR2) to stimulate leukocyte transmigration, among other effects.99  CXCL-
8 is involved in removal of L-selectin and expression of integrins on neutrophils, and 
facilitates transmigration of neutrophils across fibroblasts, endothelial and epithelial cells.  
Additionally CXCL-8 induces many neutrophil mediated immune functions including 
respiratory burst, degranulation, release of leukotriene B4 and synthesis of platelet activating 
factor.99  It should be noted that both mice and rats, do not express CXCL-8, and its orthologs 
responsible for neutrophil chemotaxis in these species include KC, MIP-2, and LIX. 
3.2. Monocyte chemoattractant protein-1 
 Monocyte chemoattractant protein-1 (MCP-1) belongs to the chemokine family of 
cytokines.100 Chemokines are small (8-10 kD) proteins primarily involved in leukocyte 
trafficking during inflammation, infection, wound healing and in health.  The term 
chemokine is reserved for proteins with a conserved structure, and many potent 
chemoattractants (C3a, C5a, leukotriene B4) are not classified as such.  MCP-1 is a CC 
chemokine, and is referred to interchangably as CC ligand 2 (CCL2) a pseudonym that 
reflects its structure rather than functionality.100 All members of the CC chemokine group 
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have the first two cysteines adjacent to each other while all members of CXC chemokine 
group have one amino acid separating the cysteines.100  The structural similarity of 
chemokines within subgroups allows for a certain degree of promiscuity in terms of 
receptor/chemokine interaction.  While chemokine receptor 2 (CCR2) is considered the main 
receptor for MCP-1 (CCL2), human MCP-1 can also bind CCR1, CCR3, and CCR5.  
Likewise CCR2 has other secondary ligands, including CCL7 and CCL12. 100,101  
3.2.1. MCP-1/CCR2 signaling 
Chemokines such as MCP-1 mediate their effects by binding to seven transmembrane 
G protein coupled receptors (GPCRs) (Figure 4).  The N terminus of the GPCR is present 
extracellularly and is the site of ligand interaction.  The intracellular C terminus interacts 
with the alpha subunit of a trimeric G protein.100,102 The G protein subunits subsequently 
dissociate and the alpha subunit is free to activate downstream effectors such as 
phospholipase C (PLC).  PLC catalyzes the formation of inositol triphosphate (IP3) and 
diacyl-glycerol (DAG).  IP3 can then open channels to release intracellular calcium into the 
cytosol while DAG activates protein kinase C (PKC).  PKC also mobilizes cellular calcium 
stores.100  Increase in intracytosolic calcium is important for the ultimate function of 
chemokine signaling, namely cell mobility.  To move along the chemotactant gradient 
requires the cell to move its cytoskeletal framework, a process dependent on polymerization 
of the actin cytoskeleton and calcium/calmodulin interactions.100  
Signaling through the GPCR may have other functions unrelated to mobility       
(Figure 4).  
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  Figure!4.!General!schematic!of!a!CC!chemokine!binding!a!chemokine!receptor.!!Chemokine!receptors!are!transmembrane!G!protein!coupled!receptors!but!are!also!linked!to!JAK/STAT!signaling!pathways.!!Chemokine!binding!can!lead!to!activation!of!multiple!downstream!signaling!cascades!resulting!in!cellular!motility!and!transcriptional!activity!among!other!functions.!
 
For instance, PKC also plays important roles in polarization and adhesion, and is also 
involved in the activation of transcription factor NF-κB mediated signaling reestablished 
after selectively restoring MyD88 function to alveolar epithelial cells.100  G proteins can also 
activate MAP kinases (p38 and ERK) which in turn activate a number of transcription factors 
(CREB and c-jun).100 Additionally, chemokine receptors can directly recruit JAK proteins, 
thereby allowing the activation of the JAK-STAT pathway, and subsequent STAT 
dimerization and translocation to the nucleus to upregulate transcription of pro-inflammatory 
cytokines.100 This paradigm proves true for murine macrophages that demonstrated tyrosine 
phosphorylation of JAK2, STAT3 and STAT5 when cultured with MCP-1.21   JAK-STAT 
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and GPCR pathways may in fact work in concert, as in some models where pharmacologic 
inhibition or mutation of JAK caused defects in both JAK-STAT and GPCR signaling 
cascades.103 
 The promiscuity of the chemokine ligand/receptor interaction and induction of 
various intracellular cascades provides a high level of plasticity and intricacy to chemokine 
signaling, which is further amplified by the finding that CCR2 has two isoforms (CCR2a, 
CCR2b), and can also form heterodimers.104-106  Early experiments evaluating isoform 
mRNA expression, and later work using isoform specific antibodies, support that CCR2b is 
the predominant form expressed.105  CCR2b/CCR5 heterodimer formation has also been 
found to occur in macrophages co-stimulated with the major ligands for these individual 
receptors, MCP-1 and RANTES (regulated upon activation, normal T cell-expressed and 
secreted) respectively, and shows preferential induction of leukocyte adhesion rather than 
chemotaxis. 106  
3.2.2.  MCP-1 physiologic and pathophysiologic roles 
 Cellular sources of MCP-1 are diverse and include macrophages and dendritic cells, 
endothelial cells, smooth muscle, fibroblasts, and some epithelial cells.  CCR2 is expressed 
on many of these same cell types such as macrophages and dendritic cells, endothelial and 
some epithelial cells and fibroblasts, as well as on other immune cells including T-
lymphocytes and neutrophils.107-17,108,109 Given the expression of CCR-2 by many MCP-1 
producing cell types, studies have demonstrated autocrine feedback.108  While chemotaxis is 
an obvious prerequisite for migration of inflammatory cells, it is also important to sessile cell 
types.  Stimulation with MCP-1 resulted in migration of endothelial cells as well as vessel 
formation and migration of epithelial cells to cover denuded areas.107,109  Some of these cells 
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constitutively produce MCP-1, production can also be upregulated or completely induced in 
other cell types, with the same being true for CCR2 expression.20,108 Stimuli that induce 
MCP-1 production or CCR2 expression vary with the cell type and model in question often 
reflecting the underlying pathophysiology.  For instance, in a model of vascular disease 
MCP-1 production was induced by oxidized lipid and shear stress.110  However other known 
MCP-1 inducers such as LPS, inflammatory cytokines (TNFα, IL-1) and a variety of TLR 
agonists are more relevant within the context of infection models.19,111,112 
3.2.2.a. The lung microenvironment 
 Pulmonary epithelial cells, alveolar macrophages, and endothelial cells are all 
possible contributors as well as targets of MCP-1 within the lung.  Both constitutive and 
inducible expression of MCP-1 has been demonstrated in human bronchial epithelial cells 
and alveolar macrophages (AMs) grown in vitro.19  In a model of bacterial pneumonia with 
Pseudomonas aeruginosa, immunohistochemistry demonstrated strong labeling of 
intracytoplasmic MCP-1 in murine alveolar epithelial cells 24 hours post infection, and in 
both epithelial cells and alveolar macrophages by 48 hours post-infection. 20  In vitro work 
also supports the expression of the CCR2 receptor on bronchiolar epithelial cells.  Human 
bronchiolar epithelial cell cultures incubated with MCP-1 were shown to upregulate both 
mucus and MCP-1 production via the CCR2 receptor. 23 In addition to initiating protective 
responses in the early phases of respiratory insult, interaction between MCP-1 and CCR-2 
bearing epithelial cells and AMs may also contribute to healing via epithelial regeneration.  
When incubated with MCP-1, alveolar epithelial cells from CCR2-/- mice or wild type mice 
(WT) treated with MCP-1 antibody showed delayed mechanical wound closure compared to 
WT controls.109  Additionally, in cell culture, MCP-1 causes murine AMs to increase the 
! 38 !
production of hepatocyte growth factor, a mitogen for bronchial and alveolar epithelial 
cells.20 
3.2.2.b. Bacterial pneumonia 
 To date the role of MCP-1/CCR2 has been investigated in a number of murine 
pneumonia models using Gram-negative agents such as Escherichia coli, Klebsiella 
pneumoniae, Burkholderia mallei, and Pseudomonas aeruginosa and the Gram-positive 
agent Streptococcus pneumoniae.17,18,101,113-115  In K.pneumoniae and E.coli models, MCP-1-/- 
mice had increased bacterial burden, decreased neutrophil influx, and attenuated 
cytokine/chemokine production and NF-κB and MAPK activation following infection as 
compared to C57Bl/6 mice.  Furthermore, through the use of migration experiments and flow 
cytometry, it was shown that neutrophils present in blood and lung express the CCR2 
receptor and migrate in response to MCP-1.17 In a similar study, E.coli endotoxin or MCP-1 
were administered as sole agents, or given in concert to immunocompetent Balb/c mice.  
MCP-1 given alone elicited monocyte recruitment without increasing pro-inflammatory 
cytokines, whereas E.coli endotoxin caused neutrophil influx and increases in pro-
inflammatory cytokines (IL-6, TNFα) and the neutrophil chemokine MIP-2 at the 6 hour time 
point.113  Interestingly, co-administration of MCP-1 and E.coli endotoxin intratracheally 
resulted in marked increase in pro-inflammatory cytokines/chemokines and a 22-fold higher 
neutrophil lavage concentration than with endotoxin administration alone, supporting the 
idea that MCP-1 may be exerting some of its neutrophil chemotactic and pro-inflammatory 
effects via synergism with endotoxin.113  
 The role of MCP-1 in innate immune response to Gram-positive bacterial pneumonia 
has only been investigated in two studies using various strains of Streptococcus pneumoniae, 
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an important pathogen in community-acquired pneumonia.  While these experiments differ in 
inoculation methods, dosage, strains of S. pneumoniae, and timeline, neither demonstrate a 
strong role for MCP-1 in neutrophil chemotaxis or pro-inflammatory cytokine production at 
early time points (6-48 hours).101,114  In one study S. pneumoniae was administered 
intranasaly at varying dosages with no difference in bacterial CFUs, inflammatory cytokine 
profiles or lethality observed over 0-48 hour time points when comparing C57Bl/6 and MCP-
1-/- mice.114  In a second study, mice were inoculated intratracheally with either a highly 
virulent or less virulent strain of S. penuemoniae. While both C57Bl/6 and MCP-1-/- mice 
were highly susceptible to the more virulent strain, C57Bl/6 mice were protected from 
mortality when challenged with the less virulent strain, as compared to MCP-1-/- mice.101  In 
contrast to the K. pneumoniae and E.coli models, this protective phenotype was most likely 
conferred by an increased influx of macrophages and dendritic cells observed at later time 
points, as no appreciable difference in cytokine/chemokine profile were observed at early 
time points and neutrophil concentrations were actually significantly higher in MCP-1-/- mice 
at 1 day post-infection.101 
 From these studies one may speculate that the role of MCP-1 in innate immune 
response to bacterial pneumonia is dictated by the presence or absence of lipopolysaccharide, 
however other Gram-negative pneumonia models may not support this conclusion.  In a B. 
mallei pneumonia model both MCP-1-/- and CCR2-/-  mice had increased mortality, local 
bacterial burdens and dissemination compared to C57Bl/6 mice at 72 hours, however CCR2-/- 
mice had increased neutrophils in the lung tissue, and increased TNFα and KC in lung tissue 
at 48 hours post-infection.115 
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 While the factors dictating how MCP-1 synergizes with pathogens such as K. 
pneumoniae and E.coli to produce robust neutrophilic responses remains unknown, a model 
of Pseudomonas aeruginosa pneumonia has provided a plausible explanation for models in 
which loss of MCP-1/CCR2 has resulted in mild to moderately increased neutrophil influx 
and cytokine production, and increased mortality.20  Mice administered anti-MCP-1 antibody 
and P. aeruginosa showed increased neutrophilic inflammation, hemorrhage and exudation 
in lung tissue, increased neutrophil concentrations and MPO activity in BALF, and 
interestingly, decreased efferocytosis as compared to control Abs-treated mice, despite no 
differences in BALF macrophage concentrations.20  In vitro work by the same group 
demonstrated macrophages co-cultured with MCP-1 and aged neutrophils exhibited 
increased phagocytosis of apoptotic cells in a dose dependent manner.20   
 These findings suggest that in some models of pneumonia increased neutrophil influx, 
persistence of MPO activity and increases in inflammatory cytokines may perhaps be due to 
a decreased efficiency of macrophages to phagocytize aged neutrophils in MCP-1-/- or AB-
blocked mice, allowing for continued release of inflammatory mediators from these dying 
cells.  Central to all of these studies however, is that among the repertoire of pathogens 
currently investigated, MCP-1 plays a protective role in innate pulmonary immune responses.  
3.2.2.c. Inflammatory and neoplastic disease 
 MCP-1 and CCR2 are of central importance to many non-infectious disease 
processes, with the MCP-1/CCR2 axis proving a promising target for pharmacologic 
blockade and therapeutic intervention.  In chronic inflammatory diseases the continued 
accumulation of macrophages can lead to fibrosis and further end-organ damage.  Studies in 
humans and rodents have demonstrated that MCP-1 levels correlate with increasing degrees 
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of fibrosis in models of pulmonary and renal fibrosis.25  Additionally MCP-1 is central to the 
pathogenesis of arteriosclerosis and re-stenosis after vascular injury as it recruits 
macrophages to the vessel wall.24  MCP-1 may also be important in many neoplastic 
diseases, owing to expression of MCP-1/CCR2 by endothelial cells and tumor infiltrating 
macrophages, both key players in neoangiogenesis.26 
3.2.3. MCP-1 therapies 
 Anti-MCP-1 therapies including MCP-1 blocking antibodies and gene therapy have 
been developed to moderate chronic or deleterious inflammatory responses, fibrosis, 
angiongenesis, and tumor burden.24-26,116  While these therapies contrast in method of 
delivery, they are functionally similar, as the end result of gene therapy is incorporation and 
transcription of a DNA sequence encoding for a non-functional MCP-1 competitive 
antagonist.25  To date parenteral administration of anti-MCP-1 antibodies have been utilized 
in a number of animal trials as well as a human trial for treatment of rheumatoid arthritis, 
while gene therapy has only been used in animal models.24-26,116  Collectively these trials 
have produced many promising results including decreasing intimal proliferation in 
artheriosclerotic plaques, reducing vessel restenosis post-angioplasty, decreasing organ 
fibrosis, and reducing overall tumor burden and angiongenesis in cancer models24-27   As 
these therapies progress towards human clinical trials, understanding the role of MCP-1 in 
innate immune defenses and delineating important risk factors for patients receiving such 
treatments becomes a priority.  
3.3. Staphylococcus aureus 
 Staphylococcus aureus is a Gram-positive bacterial cocci that can be both a 
commensal or invasive pathogen in humans.  Microscopically S. aureus appears in clusters, 
! 42 !
and when cultured can be differentiated from other types of staphylococci by positive 
coagulase, mannitol fermentation, and deoxyribonuclease testing.117  While capsular antigens 
can be used to serotype S. aureus, pulse-field gel electrophoresis (PFGE) is considered the 
method of choice for determining bacterial strain.3,117 For the purposes of simplifying 
nomenclature, the CDC assigned strain names to S. aureus based on PFGE results from 
common isolates within the United States (ie the USA strains).3  Originally 8 strains were 
identified but this number has since grown ranging from USA100-USA1200.3  Notably the 
majority of these are methicillin resistant (ie MRSA) with the exception of strains USA900 
and USA1200.3   
3.3.1. Ecology and epidemiology 
 The human nares are a well-documented site for S. aureus colonization and much of 
our data concerning prevalence of S. aureus colonization come from epidemiologic studies of 
nasal carriage.25,118-120 In one such study conducted in the United States from 2001-2004 
approximately 30% of subjects had nasal colonization with S. aureus, however a relatively 
low number of these cases were due to colonization with a MRSA strain (0.8-1.5%).120  
Colonization with S. aureus has long been considered a risk factor for development of 
invasive disease; although only a low number of those with nasal carriage go on to develop 
infection.118-120  The majority of S. aureus infections occur in the skin and soft tissues, but 
other manifestations such as pneumonia and septicemia constitute a substantial cause of 
MRSA mortality.117  In 2005 MRSA strains were responsible for 18,000 deaths in the United 
States, greater than 75% of which were caused by pneumonia.2  While within a hospitalized 
setting comorbidity such as underlying disease, immunosuppression, or recent surgery play a 
role in development of infection, community acquired cases often occur in healthy 
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individuals with no apparent risk factors.3,13,119 Given the dissimilarities between community 
and hospital acquired S. aureus infections, they are addressed individually below with a 
predominate focus on MRSA. 
3.3.1.a. Community acquired MRSA  
 Community acquired MRSA (CA-MRSA) refers to cases that lack an association 
with health care.  Other traits that typify CA-MRSA often include PFGE type USA300 and 
genes encoding certain virulence factors that are often expressed by, but not specific to, 
USA300.3,119,120 In addition, while the name itself implies resistance to β-lactam antibiotics, 
CA-MRSA strains are generally susceptible to a wider range of antibiotics than hospital or 
ventilator acquired strains (HA/VAP-MRSA).119,121  USA300 was recognized as a 
predominant  cause of CA-MRSA in the late 1990s and early 2000s, before which USA400 
was the most frequent isolate.3,119  While these outbreaks often occurred among seemingly 
healthy individuals including members of sports teams and military units, these cases did 
highlight potential risk factors including shared use of personal items (towels/razors), 
previous antibiotic use, or ineffectual wound care.3  A multi-institutional survey conducted in 
2006 indicated MRSA strain USA300 to be the leading cause of skin and soft tissue 
infections among emergency room patients.11   
 While USA300 less commonly causes pneumonia, when it occurs, it is often severe, 
necrotizing and fatal.  The necrotizing and hemorrhagic features of USA300 pneumonia are 
well-documented, however a conserved mechanism to explain development of these lesions 
has yet to be delineated.7  A commonly implicated contributor is Panton-Valentine 
leukocidin, a virulence factor expressed by many USA300 isolates, but other factors are 
likely at play, as strains not expressing this virulence factor have been documented to cause 
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similar lesions.8  For individuals developing MRSA as a result of compromised immunity 
after influenza infection, interferon may play an important role.13  In murine models severe S. 
aureus pneumonia can be induced at lower inoculum dosages in animals previously infected 
with influenza.122  Additionally mice deficient in interferon-α/β receptor 1, which are 
incapable of responding to interferon, were protected from a lethal challenge with S. aureus 
as compared to wild type mice.16  
3.3.1.b. Hospital/Ventilator acquired MRSA 
 Hospital acquired MRSA (HA-MRSA) and ventilator acquired pneumonia due to 
MRSA (VAP-MRSA) pose a significant health risk to hospitalized populations, with reported 
mortality rates as high as 37%.4  Prior to the rise of USA300 in CA-MRSA, commonly 
isolated HA-MRSA strains included USA100, USA200, and USA500.119  While both CA 
and HA-MRSA strains are resistant to methicillin, the genetic determinants which confer this 
resistance differ, with HA-MRSA strains often showing resistance to a wider array of 
antibiotic classes.119,121 As USA300 continues to be the most prevalent cause of CA-MRSA 
cases, these distinctions are becoming less clear and growing epidemiologic evidence 
supports that USA300 is also now a leading cause of HA-MRSA.4  In 2012, MRSA isolates 
from 251 intensive care unit (ICU) patients were obtained and while USA100 predominated 
(55%), USA300 was the second most common isolate (23.9%).4   
 Compared to HA/VAP caused by methicillin sensitive strains, HA/VAP MRSA is 
documented to have increased mortality, and is responsible for increased utilization of 
hospital resources and cost burden, with treatment of MRSA cases averaging $8,000 more 
than MSSA cases in one retrospective.5,6 Infection with HA/VAP may occur in patients with 
nasal colonization, although transient skin colonization of health care workers and patients is 
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also a proposed mode of transmission.  Interestingly a genotypic determinant named arginine 
catabolix mobile element (acme) present in some isolates of USA300 may improve fitness 
and increase the ability of the organisms to remain on the skin by encoding an arginine 
deaminase, which allows for the formation of ammonia.  This pathway may allow USA300 
to maintain its pH in the relatively acidic environment of human skin.123  If this is indeed the 
case, much of our current epidemiologic investigations involving MRSA may be far from 
complete, as they focus largely on screening via nasal carriage.  
3.3.2. Major virulence factors  
3.3.2.a. Protein A 
 Protein A (Spa) is a well-studied and abundant S. aureus surface protein.  Although 
Spa serotyping was often employed in older epidemiological studies of S. aureus, this has 
largely been surplanted by newer molecular techniques.  While PFGE is the gold standard for 
classification of  S. aureus strains the Xr region of spa  is highly genetically diverse, and 
provides the basis for spa typing.13  Immunologically, the Xr region is responsible for 
promoting a type I interferon response.  Spa encoding strains have been shown to induce 
IFN-β production in pulmonary epithelial cells.16  Interestingly this type I interferon response 
increases the pathogenicity of S. aureus in the context of pneumonia, as demonstrated by 
Ifnar-/- mice which are protected from lethal S. aureus challenge as compared to wild type 
mice.13  These findings provide some mechanistic support for the long held observation that 
individuals acquiring S. aureus pneumonia as a sequel to influenza, a potent inducer of the 
type I interferon response, suffer dramatically increased morbidity and mortality.13    
 Spa is equipped with 5 IgG binding domains that bind the Fc component of IgG.  
These structures have proven useful experimentally, as they provide the basis for 
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immunoprecipitation experiments, however conflicting information exists as to if coating 
with IgG protects the organism from phagocytosis as originally thought.13  Spa is also 
capable of binding immunoglobulin receptors, notably the B-cell IgM receptor, which has 
earned it the term B-cell super antigen.124  Binding of the B-cell IgM receptor is believed to 
cause rapid clonal expansion and apoptosis of B-cells, ultimately resulting in the inability to 
mount an effectual B-cell response to the organism.13 
 The IgG binding domains mentioned above are relatively promiscuous, and have also 
been demonstrated to bind TNFR1, EGFR, and ADAM17.125-127  Binding of TNFR1 induces 
TNF production, where as binding to EGFR can lead to cleavage of TNFR-1 and ADAM17 
binding produces soluble proteins that neutralize IL-6.126,127 Thus, depending on the context, 
spa can generate both pro and anti-inflammatory cytokine responses.   
3.3.2.b. α-Hemolysin 
 α-Hemolysin (Hla) is a ubiquitously expressed S. aureus heptameric pore-forming 
toxin which penetrates eukaryotic lipid bilayers.  It is a well-documented contributor to S. 
aureus induced lung pathology, with a broad range of target cells including histiocytes, 
epithelial cells and endothelial cells.13  The cellular receptor for α-Hemolysin, ADAM-10, is 
a matrix metalloproteinase which regulates cellular adhesion and mobility.128  The Hla-
ADAM10 interaction has been shown experimentally to disrupt focal cellular adhesions and 
integrin signaling in epithelial cells and cause vascular endothelial-cadherin cleavage and 
loss of endothelial barrier function.128,129 This relationship may explain some of the 
pathology induced by α-Hemolysin including pulmonary hemorrhage and edema formation.13  
Additionally it provides a putative mechanism for S.aureus dissemination throughout the 
lung, as well as systemically, via interaction with endothelial cells, granting the organism 
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access to the blood stream.128,129  Regardless of the exact mechanisms, experimental evidence 
supports the important contribution of this interaction to lung pathology, as ADAM-10-/- mice 
were found to be significantly less susceptible to fatal S. aureus pneumonia as compared to 
wild type mice.13 α-Hemolysin also serves as a ligand for the NLRP3 inflammasome, leading 
to induction of IL-1β and IL-18 production and pyroptosis.75 
3.3.2.c. Panton-Valentine leukocidin 
 Panton-Valentine leukocidin (PVL) is a pore-forming toxin shown to cause apoptosis 
of neutrophils in low doses and neutrophil necrosis in high doses.  These effects appear to 
vary with species, and have been demonstrated in humans and rabbit models, where as 
murine neutrophils appear relatively resistant.9,10 In addition to inducing inflammation via 
leukocyte necrosis, PVL has been shown experimentally to induce transcription of genes 
encoding for pro-inflammatory cytokines in alveolar macrophages.  PVL mediated gene 
transcription occurs in an NF-κB mediated manner, resulting in upregulation of TNF-α and 
MIP2.130  This function appears to be mediated via binding of PVL to TLR2, and occurs 
independent of its pore forming capabilities.130   
 While by no means pathognomonic, the severe necrotizing and hemorrhagic 
pneumonia seen in many cases of CA-MRSA is characteristic of USA300 infection.  PVL, 
which is expressed by a large number of USA300 isolates, and by relatively few other MRSA 
or MSSA strains, has often been implicated as a major cause of these pathologic changes.8,9  
It is unlikely, however, to be the sole mediator, as similar pathologic lesions are described 
post-infection with USA300 strains not expressing PVL.8  Furthermore, conflicting 
information exists as to PVL expression and clinical outcome.  Another virulence factor that 
may contibute are phenol soluble modulins (PSMs).  PSMs have been shown experimentally 
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to have similar leukocytic effects, which may also be relevant in a broader range of host 
species.9,11   
3.3.2.d. Super antigens  
 Super antigens (SAgs) are molecules that stimulate T-cell hyperactivation resulting in 
massive cytokine release, and underpin the pathogenesis of toxic shock syndromes associated 
with certain strains of Staphylococcus and Streptococcus.  SAgs exert this effect by 
sidestepping traditional antigen presentation, and bind MHC class II molecules of antigen-
presenting cells and the variable region of the T-cell receptor β-chain simultaneously.12  This 
allows SAgs to activate all T-cells expressing a Vβ-TCR (as much as 50% of cells) rather 
than the 0.01% of T-cells that would normally respond to an antigen.12  While most described 
SAgs are small-secreted molecules encoded on mobile elements with variable strain 
expression, recently staphylococcal enterotoxin like toxin (Selx) has been discovered, which 
is a super antigen encoded by the core genome of over 95% of S. aureus strains, including 
MRSA 300.  Expression of Selx by USA300 does appear to interact with the Vβ-TCR, and 
contribute to the necrotizing pneumonia characteristic of USA300 in a rabbit model of 
pneumonia.12  
3.3.3. Host immune response  
 Various cell wall components of S. aureus (peptidoglycan, lipoteichoic acid, 
lipoprotein) are recognized by PRRs including TLR2, NOD2 present on resident epithelial 
cells and alveolar macrophages, as well as by the soluble PRRs mannose binding lectins and 
ficolins.14  While association with lectins and ficolins marks S. aureus for complement 
mediated destruction it may prove ineffectual as the bacteria encodes many complement 
blocking proteins.13 Additionally, while mice deficient in the TLR2 adaptor protein MyD88 
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are highly susceptible to systemic infection with S. aureus, these mice are able to control 
pulmonary infection with maintained cytokine/chemokine and neutrophil responses.14  In 
contrast NOD2-/- mice challenged intratracheally with S. aureus do have diminished 
cytokine/chemokine responses and neutrophil influx, however, reduced inflammatory 
signaling in this model lead to improved bacterial clearance.15  These findings illustrate the 
complex interaction between the pathogen and host, and stress the necessity of in vivo 
models to assess the true relative contributions of putative immune players. 
 While undoubtedly some degree of pro-inflammatory signaling is necessary for 
bacterial clearance and neutrophil recruitment, it remains unclear which signaling cascades 
are vital, dispensable, or actually counter productive for protective immunity.  Despite its 
role in neutrophil chemotaxis and ability to augment neutrophil and macrophage mediated 
microbe killing, higher TNF-α concentrations are not necessarily protective. In one study 
TNF-α levels were inversely correlated with outcome in an S. aureus pneumonia model.13  
Likewise mice deficient in TNFR1 clear S. aureus more efficiently than wild type mice, 
however this effect may be mediated by decreased binding of not only TNF- α, but also 
Protein A, an S. aureus virulence factor known to bind and signal through this receptor.16 
  Numerous S. aureus derived antigens such as capsular antigens, staphylococcal 
enterotoxin A and B, and lipoteichoic acid, as well as host derived substances such as the 
complement component C5a contribute to neutrophil chemotaxis and induction of IL-8.1 In 
addition to IgG binding domains of protein A and complement inhibitors encoded by S. 
aureus preventing its phagocytosis, the bacteria also encodes proteins that promote its 
survival post phagocytosis.  These include the pore forming HLA or PVL that can liberate 
the organism from phagocytic cells, and catalase and proteases to combat both oxygen 
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dependent and independent killing.1  Additionally phagocytosis of S. aureus can accelerate 
apoptosis of neutrophils, resulting in secondary lysis of neutrophils and release of their 
inflammatory contents prior to efficient efferocytosis by macrophages.1 
 Regardless of these varied immune evading techniques organisms are none the less 
readily phagocytized and killed by neutrophils, and there is long standing evidence 
supporting the critical role of neutrophils in clearance of S. aureus from the lungs.  This point 
is illustrated in people afflicted with immune-deficiencies involving neutrophil function, such 
as chronic granulomatous disease and hyper IgE syndromes, in which the incidence of 
recurrent and unresolving S. aureus infections are well-documented.1  Left unchecked, 
however, neutrophils can impart as much harm to the surrounding tissue as to the pathogen 
via toxic mediators such as elastase, collagenase, and free radicals.1  The factors delineating 
what constitutes a protective versus harmful immune response to S. aureus continue to be 
elusive, warranting further studies into the pulmonary innate immune response to this 
important pathogen.  
3.3.4. Animal models  
 The majority of in vivo animal studies have been performed in mice.13  Given the 
ready availability of specific gene deficient strains, murine models have offered much insight 
into immunologic responses during S. aureus infection.  One major limitation of the murine 
model is the relative resistance of mice to S. aureus infection, developing only mild disease 
at doses of 1x108 CFU/ml, with as much as 3-4x108 CFU/ml constituting a “high dose” 
causing significant mortality.131  Additionally while PVL causes neutrophil influx to murine 
lungs, the toxic pore forming principle does not appear to affect murine leukocytes.130 The 
failure of murine models to recapitulate the severity of human USA300 pneumonic lesions 
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has lead to the use of a rabbit model. While rabbits also require much higher inoculation 
dosages of S. aureus than would be expected in naturally occurring human pneumonia, they 
are similarly sensitive to PVL and the T cell superantigen Selx, both of which appear to 
contribute to severe hemorrhagic pneumonia in this species.10,12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 52 !
CHAPTER 4 
MATERIALS AND METHODS 
 
4.1. Mice 
  8- to 10-week-old female mice genetically deficient in MCP-1 (Jackson 
Laboratories) were used, while age- and gender matched C57Bl/6 mice were used as 
controls.132 Animal studies were approved by the Louisiana State University Animal Care 
and Use Committe. The mice ranged from 19 to 25 g in weight. 
4.2. Infection model 
  Bacteria were prepared for mouse inoculation, as described in previous studies.133 
Methicillin resistant S. aureus (MRSA) strain USA300 (from F. DeLeo, Rocky Mountain 
Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, MT) was 
grown in Trypticase soy broth (TSB) at 37°C overnight under constant agitation. Bacteria 
were harvested, washed, and resuspended in sterile 0.9% saline at a concentration of 20x108 
CFU/ml. Mouse strains were anesthetized with intraperitoneal ketamine-xylazine (250 
mg/kg), followed by intratracheal (i.t.) inoculation of 50 ul of bacteria (108 CFU/mouse). The 
initial mouse inocula were confirmed by plating serial 10-fold dilutions on tryptic soy agar 
(TSA) plates. For enumerating bacterial CFU in the lung, liver and spleen, whole spleens and 
whole lung and liver lobes were homogenized in 1 ml sterile deionized water for 30 s, and 20 
ul of the resulting homogenates was plated by serial 10-fold dilutions on TSA plates.  
Bacterial colonies were counted after incubation overnight at 37°C.  
4.3. Blocking antibodies 
  C57Bl/6 mice were treated i.t. with MCP-1 (R&D systems) or IgG2B antibody (10 
ug/mouse) 30 minutes prior to S. aureus infection (108 CFUs/mouse). 
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4.4. Bronchoalveolar lavage fluid collection 
 Bronchoalveolar lavage fluid (BALF) was collected, and total and differential cell 
counts and cytokine/chemokine levels were determined. Approximately 3 ml of lavage fluid 
was retrieved per mouse. Total leukocytes in BALF were determined using a hemocytometer. 
Cytospin samples were subsequently prepared from BALF cells and stained with Wright-
Geimsa. Differential cell counts were determined by direct counting of stained slides. For 
examination of cytokines/chemokines, the remainder (2 ml) of the undiluted cell-free BALF 
was used immediately or stored at -80°C. 
4.5. Cytokine and chemokine ELISA 
  We used BALF and lungs that were obtained from animals after S. aureus infection 
or control animals. Enzyme-linked immunosorbent assay (ELISA) kits for tumor necrosis 
factor alpha (TNF-alpha), interleukin-6 (IL-6), Interleukin-1β (IL-1β), Interleukin-17 (IL-
17), IL-17A, and IL-17F and MCP-1 were obtained from eBiosciences, PA, whereas kits for 
KC and MIP-2 and LIX were obtained from R&D Systems, MN. The minimum detection 
limit is 8 pg/ml cytokine protein.  
4.6. Myeloperoxidase activity assay 
  Myeloperoxidase (MPO) release by the neutrophils was measured as previously 
described.134  
4.7. Histopathology 
 The lungs of C57Bl/6 and MCP-1-/- mice were perfused from the right ventricle of the 
heart with 10 ml isotonic saline at 6 hours and 24 hours post-infection. Lungs 
were then removed and fixed in 4% phosphate-buffered formalin. Fixed tissue samples were 
processed in paraffin blocks, and 5µm sections were cut with a microtome and stained with 
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hematoxylin-eosin (H&E). Analysis of histopathology was performed in blinded fashion by a 
veterinary pathologist using an amended version of a previously published scoring system 
(Table 1) with scores for each category assigned to individual lung lobes based on 
microscopic assessment at an objective of x400.135 
4.8. Statistics 
 All statistical calculations were performed using GraphPad Prism (version 5.0) 
software. Data are displayed as median and interquartile ranges.  Groups were compared 
using the Wilcoxon rank-sum test.  Differences were considered significant at *p<0.05; 
**p<0.01;***p<0.001.
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 Figure 5. Quantitative scoring of lung histopathology. 
 
! 56 !
CHAPTER 5 
RESULTS 
 
5.1. MCP-1-/- mice have increased neutrophils in the airways and lung parenchyma post      
S.aureus challenge 
 
 Recruitment of leukocytes, specifically neutrophils, is an important step in achieving 
clearance of  S. aureus as well as other bacterial pathogens. To investigate the extent of 
leukocyte recruitment to the airways, we determined total and differential leukocyte counts in 
BALF at 6 and 24 hours post-infection with S. aureus (108 CFU/mouse).  We observed that 
both C57Bl/6 and MCP-1-/- mice responded to S. aureus challenge with increased leukocyte 
influx at 6 hours with highest concentrations measured at 24 hours, and that in both groups 
neutrophils predominated [Figure 6 (6a and 6c)].  Additionally, while total leukocyte and 
neutrophil concentrations were similar between experimental groups at 24 hours, MCP-1-/- 
mice had increased numbers of neutrophils at the 6 hour time point [Figure 6 (6a and 6c)].  
To assess neutrophil activity and infiltration of lung tissue, a myeloperoxidase activity assay 
was performed on lung tissue from MCP-1-/- and C57Bl/6 mice.  While both experimental 
groups showed increased MPO activity in lung homogenates, with highest activity at 24 
hours post-infection, MCP-1-/- mice had significantly higher MPO activity at both 6 hours 
and 24 hours [Figure 6 (6a and 6c)].  Intraalveolar inflammation and tissue involvement were 
assessed in individual lung lobes from C57Bl/6 and MCP-1-/- mice. Higher scores for 
intraalveolar inflammation and tissue involvement were more frequent in lung lobes from 
MCP-1-/- mice at 6 hours, at which time 9/10 had a score of 1 for intraalveolar inflammation, 
and 9/10 a score of 1 or 2 for tissue involvement, compared to a score of 0 in 9/10 lobes from 
C57Bl/6 mice for both intraalveolar inflammation and tissue involvement (Figure 7).  At 24 
hours post infection scores of 1 and 2 for both intraalveolar inflammation and tissue 
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involvement predominated, and occurred in similar frequency between groups.  Alveolar 
hemorrhage and congestion of alveolar septae were also evaluated histologically and 
appeared similar between groups.     
 
 
Figure 6. Leukocyte recruitment to airways and lungs of MCP-1-/- mice . A MCP-1-/- mice 
have increased concentrations of leukocytes in BALF at 6 hours post S. aureus infection as 
compared to C57Bl/6 mice.  Both experimental groups have increased concentrations of 
leukocytes in BALF post- infection as compared to negative controls (NC) (levels of 
significance not graphically displayed). B MCP-1-/- mice have increased myeloperoxidase 
(MPO) activity in lung tissue at 6 and 24 hours post S. aureus infection as compared to 
C57Bl/6 mice.  Both experimental groups have increased MPO activity as compared to 
negative controls (NC) (levels of significance not graphically displayed).  C  Representative 
cytocentrifuged preparation of BALF from a C57Bl/6 mouse (top) and MCP-1-/- mouse 
(bottom) 6 hours post S. aureus infection. 50x objective, Wright-Geimsa (WG). Inset: a 
neutrophil containing clusters of bacterial cocci. 100x objective WG. 
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Figure 7. Lung histology in MCP-1-/- mice following S. aureus infection. Mice were 
inoculated with S. aureus (108 CFU/mouse), lungs were obtained at 6 hours post-infection. 
This picture is a representative of 2 separate mice with comparable results.  
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5.2. MCP-1-/- mice have increased levels of inflammatory cytokines at 6 hours post S. aureus 
infection 
 
 Numerous cytokines and chemokines produced during inflammation can exert effects 
on neutrophil dynamics and recruitment.  Since neutrophil recruitment appeared enhanced at 
the 6 hour time point in MCP-1-/- mice, we examined the concentrations of many known 
inflammatory mediators of neutrophil recruitment in BALF and lung tissue.  We found 
increased concentrations of the inflammatory cytokines TNF-α and IL-6 in MCP-1-/- mice at 
the 6 hour time point (Figure 8).  IL-1β increased in both experimental groups with infection 
but was not significantly different between groups.  The neutrophil chemoattractant 
chemokines KC, MIP-2, and LIX increased with infection and LIX concentration were 
significantly higher in MCP-1-/- mice 24 hours post-infection (Figure 8). 
5.3. Local bacterial burden and dissemination are equivocal in MCP-1-/- and C57Bl/6 mice 
 While adequate neutrophil recruitment is a proven necessity in bacterial clearance, 
protective immunity does not always correlate directly to neutrophil numbers.  In some 
models excess neutrophil accumulation and/or pro-inflammatory cytokine production are 
accompanied by poor prognosis and outcome in S. aureus infection.1  For this reason we 
assessed both local bacterial burden and dissemination as determined by bacterial load in 
BALF, lung, liver and spleen.  Mice were infected with S. aureus i.t. and sacrificed at 6 and 
24 hours post-infection and BALF, lung, liver, and spleen were collected to quantitate 
bacterial CFUs.  While both experimental groups had highest bacterial burdens in BALF and 
lung at 6 hours that decreased at the 24 hour time point, MCP-1-/- mice had significantly 
fewer bacterial CFUs in BALF at 6 hours as compared to C57Bl/6 mice (Figure 9).  
Dissemination to the liver and spleen was present at 6 hours and persisted at 24 hours in both 
groups (Figure 9).      
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Figure 8. Cytokine and chemokine profile in MCP-1-/- mice. A Cytokine Profile. MCP-1-/- 
mice have increased concentrations of IL-6 and TNF-α in BALF at 6 hours post- infection 
compared to C57Bl/6 mice.  Experimental groups have increased concentrations of IL-6 and 
TNF-α as compared to negative controls (NC) (levels of significance not graphically 
displayed, IL-6 and TNF-α NC below detection limit). IL1-β levels increase with infection 
but are not different between experimental groups (levels of significance not graphically 
displayed). B Chemokine Profile.  MCP-1-/- mice have higher levels of LIX at 24 hours post-
infection compared to C57Bl/6.  MIP-2 levels are higher in negative control C57Bl/6 than 
MCP-1-/- mice.  For both groups KC and MIP-2 increase significantly at 6 hours and decrease 
significantly by 24 hours, whereas LIX continues to increase at 24 hours post-infection 
(levels of significance not graphically displayed, KC below limit of detection for NC).   
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Figure 9. Bacterial burden in MCP-1-/- mice. MCP-1-/- mice have lesser numbers of bacterial 
CFUs in BALF at 6 hours post S. aureus infection as compared to C57Bl/6 mice.  BALF and 
lung CFUs decrease in both experimental groups 24 hours post- infection.  Bacterial 
dissemination is present in liver and spleen at 6 hour and 24 hour time points. 
 
5.4. MCP-1 AB-blocked mice trend towards higher BALF leukocyte concentrations and lung 
MPO activity 
 
 The same infection model was performed using MCP-1 and isotype control AB-
blocked mice to ensure that the MCP-1-/- phenotype correlated with that of MCP-1 AB 
blocked animals.  MCP-1 AB blocked mice trended towards higher total leukocyte 
concentrations in BALF and higher MPO activity in lung tissue, despite similar CFU in 
BALF and lung homogenates (Figure 10). A cytokine/chemokine profile including IL-6, 
TNF-α, IL-1β, KC, MIP2, and LIX revealed no significant differences between groups, with 
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the exception of LIX, which was higher in MCP-1 AB blocked mice at 6 hours post-infection 
(Figure 11).  
 
 
               
                
 
 
Figure 10.  Neutrophil recruitment to the lungs and airways and local bacterial burden in 
MCP-1 AB-blocked mice. MCP-1 AB blocked mice trend towards higher leukocyte counts 
in BALF and higher MPO activity in lung tissue as compared to AB-blocked control mice.  
Bacterial CFUs do not differ between groups, but do decrease significantly by 24 hours post-
infection in both experimental groups (level of significance not graphically displayed.)  
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Figure 11. Cytokine and chemokine profile in MCP-1 AB-blocked mice. MCP-1 AB blocked 
mice have higher levels of LIX at 6 hours post S. aureus infection, while levels of IL-6, TNF-
α, IL-1β, KC, and MIP2 do not differ between groups. 
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CHAPTER 6 
DISCUSSION 
 
 Adequate neutrophil recruitment to the lungs and airways is vital for protective 
immunity against a number of pulmonary pathogens including S. aureus.  In E.coli and K. 
pneumoniae models MCP-1 enhances neutrophil recruitment and bacterial clearance, 
however in our model MCP-1-/- mice had higher neutrophil numbers in BALF, and increased 
MPO activity in lung tissue, with no appreciable improved bacterial clearance.17,18 A number 
of other pneumonia models support increased neutrophil influx to the lungs and increased 
pro-inflammatory cytokine profiles in MCP-1-/- or CCR2-/- mice including studies with the 
gram negative pathogen Burkholderia mallei and the gram positive pathogen S. pneumoniae.  
Interestingly, MCP-1 was still protective in these models, with knock out mice demonstrating 
increased mortality and bacterial burden as compared to wild type controls.101,115 Unlike in 
the E.coli and K. pneumoniae models, however, the protective role of MCP-1 appeared to be 
via recruitment of macrophages to airways at later time points, rather than an effect on 
neutrophil recruitment.  
 Increased numbers of neutrophils present in the airways and lungs of MCP-1/CCR2-/- 
mice may be the result of one or more of three general mechanisms.  Firstly MCP-1/CCR2-/- 
mice may produce an altered inflammatory signaling cascade during certain infections 
leading to the generation of increased neutrophil chemotactic molecules as compared to wild 
type mice.  Second, neutrophil lifespan may be prolonged/enhanced in the absence of MCP-
1/CCR2.  Thirdly MCP-1/CCR2-/- mice may have impaired clearance of senescent 
neutrophils.   
 In our model IL-6 and TNF-α concentrations were higher in MCP-1-/- mice, but 
neutrophil chemotactic substances (KC, MIP2, LIX) were not significantly different between 
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groups, with the exception of higher LIX in MCP-1-/- mice at the 24hr time point, and higher 
MIP2 in C57B/l6 mice at baseline.  Ultimately, however, sample collection at the 4 hour time 
point would have been ideal to asses if neutrophil chemotactic molecules were higher in 
MCP-1-/- mice prior to the increased influx of neutrophils to the lung and airways noted in 
this group at 6 hours.  The increased concentration of LIX at the 24 hour time point may 
simply reflect the slower kinetics of this chemokine compared to KC and MIP2 as has been 
previously reported.136  A biological reason for the difference in MIP2 between control 
groups is less evident, and may simply be a statistically relevant but biologically irrelevant 
difference, reflective of low sample size. 
  While chemokine receptors generate many down-stream signaling cascades, no 
experimental evidence currently exists to support the conclusion that neutrophil lifespan is 
regulated via the MCP-1/CCR2 axis, or would be enhanced in the absence of MCP-1/CCR2 
signaling, making this scenario less likely.  There is, however, currently experimental support 
that MCP-1 deficient mice demonstrate decreased efferocytosis of senescent neutrophils, 
which may contribute to secondary necrosis of these cells, prolonging both pro-inflammatory 
signaling and neutrophil number and MPO activity in tissue. 
 Mice administered anti-MCP-1 antibody and P. aeruginosa showed increased 
neutrophilic inflammation, hemorrhage and exudation in lung tissue, increased neutrophil 
concentrations and MPO activity in BALF, and interestingly, decreased efferocytosis as 
compared to control Abs-treated mice, despite no differences in BALF macrophage 
concentrations.20!!In vitro work by the same group demonstrated macrophages co-cultured 
with MCP-1 and aged neutrophils exhibited increased phagocytosis of apoptotic cells in a 
dose dependent manner.20 These findings suggest that in some models of pneumonia 
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increased neutrophil influx, persistence of MPO activity and increases in inflammatory 
cytokines may perhaps be due to a decreased efficiency of macrophages to phagocytize aged 
neutrophils in MCP-1-/- or AB-blocked mice, allowing for continued release of inflammatory 
mediators from these dying cells. 
 While our model shares similarities with some of those previously mentioned (S. 
pneumoniae, B. mallei, P. aeruginosa) in terms of immune response generated, these 
experiments also demonstrated increased bacterial burden and/or mortality in MCP-1/CCR2-/- 
mice, findings that were not present in our study.  One explanation for this is the relative 
resistance of mice to S. aureus pneumonia.  The inoculum dose used in this experiment 
(1x108 CFU/mouse), which would be exceedingly high for other important pulmonary 
pathogens such as K. pneumoniae or S. pneumoniae, is considered a low i.t. dose of S. aureus 
for mice.131  This is consistent with other pulmonary inoculation models in which S. aureus 
doses of 3-4x108 CFU/mouse are considered a high dose inoculum resulting in significant 
mortality.131  If high dose inoculum had been used in the current experiment, it may have 
allowed for significant differences to emerge between MCP-1-/- and C57Bl/6 mice with 
respect to bacterial burden and tissue damage as assessed histologically. 
 The experimental protocol used in MCP-1-/- and C57Bl/6 mice was also performed in 
antibody-blocked mice for two main reasons.  First, administration of anti-MCP-1 antibody 
has more translational relevance, as it is most similar to the techniques currently employed in 
experiments assessing efficacy of anti-MCP-1 antibodies and gene therapy.  Second, 
correspondence between MCP-1-/- and antibody blocked phenotypes supports the conclusion 
that differences present between experimental groups are directly related to MCP-1/CCR2 
signaling, rather than any intracellular alterations in gene expression, transcription, or 
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translation of proteins that may be occurring in MCP-1-/- as a results of gene deletion.  While 
antibody blocked mice did not recapitulate the phenotype of MCP-1-/- mice, BALF leukocyte 
concentration and MPO activity in lung tissue did trend in similar directions, and LIX was 
significantly higher in MCP-1 AB blocked mice at the 6 hour time point.  We originally 
attempted antibody blocking at a dose of 1ug/mouse and did not observe this trend (data not 
shown) supporting the concept that 10 ug/mouse may still be a suboptimal dose of blocking 
antibody.  Ultimately we expect that MCP-1-/- and AB-blocked phenotypes correspond, as 
this has been demonstrated in other models.  However to date these experiments have 
employed systemic administration of Anti- MCP-1 antibody, and an effective intrapulmonary 
dose remains to be described.20  
 Ultimately how MCP-1 is differentially regulated in models of pneumonia, causing 
robust and protective neutrophil influx in K. pneumoniae and E. coli models while absence of 
MCP-1/CCR2 in other models results in ineffectual bacterial clearance despite augmented 
neutropilic responses, remains unclear.  Central to all of these studies however, is that among 
the repertoire of pathogens currently investigated, MCP-1 plays a protective role in innate 
pulmonary immune responses.  It is likely that MCP-1 plays a protective role in pulmonary S. 
aureus infection as well, however further studies are warranted; both to more clearly 
delineate the pathology in MCP-1-/- mice using a higher S. aureus inoculation dosage, and 
also to investigate the putative role of MCP-1 in efferocytosis in this model. 
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